Guideline 29.01.2026

İyi Klinik Uygulamaları Kılavuzu

EN: This is the official English version published by the authority (TİTCK), imported from the AIFD Legislation Portal archive. The binding text is the official Turkish version.

İyi Klinik Uygulamaları Kılavuzu_EN

SöğütözüMahallesi,2176.SokakNo:506520Çankaya/Ankara Telephone:(0312)2183000Fax:(0312)2183460 E-mail:[email protected] Web:https://www.titck.gov.tr/ KEP:[email protected] TurkishMinistryofHealth TurkishMedicinesandMedicalDevicesAgency GUIDELINEONGOODCLINICALPRACTICE KAD-KLVZ-01 InitialVersionEffectiveDate 29.12.1995 1 st RevisionEffectiveDate 28.01.2009 2 nd RevisionEffectiveDate 28.05.2010 3 rd RevisionEffectiveDate 10.12.2010 4 th RevisionEffectiveDate 06.12.2011 5 th RevisionEffectiveDate 23.08.2011 6 th RevisionEffectiveDate 17.04.2013 7 th RevisionEffectiveDate 15.07.2014 8 th RevisionEffectiveDate 01.02.2024

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 2of34 1.INTRODUCTION Goodclinicalpracticeisanethicalandscientificqualitystandardfordesigning,conducting,recording, andreportingclinicaltrialsinhumansubjectsbasedonprincipleslaiddownintheDeclarationof Helsinki. Compliancewiththisstandardprovidespublicassurancethattherights,safetyandwell-beingof clinicaltrialsubjectsareprotected,andthattheclinicaltrialdataarecredible. TheobjectiveoftheGuidelineonGoodClinicalPracticeistoprovideaunifiedstandardtofacilitate mutualacceptanceofclinicaldatainternationally. ThisguidelineprovidesguidanceoncollectionofclinicaldataforsubmissiontoTurkishMedicines andMedicalDevicesAgencyandethicscommittees,andlaysdowntheparticularsandprinciplesfor clinicaltrialswhichareconductedorproposedtobeconductedinTürkiye. 2.DEFINITIONS 2.1AdverseEvent:Anyuntowardmedicaloccurrenceinaclinicalinvestigationsubjectwhichdoes notnecessarilyhaveacausalrelationshipwiththetreatmentadministered. 2.2AdverseReaction:Anynoxiousandunintendedresponsestoaninvestigationalproductoccurring inaclinicalinvestigationsubject. 2.3Investigator:Aphysicianordentistdesignatedbytheprincipalinvestigatorforimplementing study-relatedcriticalproceduresortakingstudy-relatedimportantdecisionsunderthesupervisionand oversightoftheprincipalinvestigator. 2.4Investigator’sBrochure:Acompilationoftheclinicalandnonclinicaldataontheinvestigational product. 2.5StudyProtocol:Adocumentthatdetailstheobjectives,design,methodology,statisticalmethods tobeemployedandorganizationofaclinicaltrial. 2.6AmendmenttoStudyProtocol:Adocumentdescribingchangesinthestudyprotocol. 2.7InvestigationalProduct:Ahumanmedicinalproducttestedorusedasreferenceinaclinicaltrial, includingplacebo. 2.8IndependentDataMonitoringCommittee(DataMonitoringGrouporDataSafety MonitoringCommittee):Acommitteeofindependentexpertsnotinvolvedintheclinicaltrial, establishedtoassessatintervalstheprogressofaclinicaltrial,thesafetydata,andthecriticalefficacy endpoints,whereappropriate,torecommendtothesponsorwhethertocontinue,modify,orstopatrial. 2.9UnexpectedSeriousAdverseReaction:Anyseriousadversereaction,thenature,severityor outcomeofwhichisnotconsistentwiththereferencesafetyinformationofaninvestigationalproduct. 2.10Subject’sInformedConsentForm(ICF):Awrittendocument,showingthatthesubjectortheir legalrepresentativehaveagreedtoparticipatinginthestudy,havingbeengivendetailedand comprehensibleinformationonthestudy. 2.11ValidationofComputerizedSystems:Aprocessofestablishinganddocumentingthatthe specifiedrequirementsofacomputerizedsystemcanbeconsistentlyfulfilled.Thevalidationprocess shouldassureaccuracy,reliabilityandconsistentperformancefromdesignuntildecommissioningof thesystemortransitiontoanewsystem. 2.12Bioequivalence:Bioavailability(rateandextent)oftwomedicinalproducts,whichcontainthe sameactivesubstanceandwhicharepharmaceuticallyequivalentorpharmaceuticalalternatives, beingwithinthepredefinedacceptancelimits,afterbeingadministeredinthesamemolardosebythe samerouteofadministration.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 3of34 2.13Bioavailability:Therateandextenttowhichtheactivesubstanceoractivemoietyis absorbedfromapharmaceuticalformandbecomesavailableinthegeneralcirculationorat thesiteofactionorinrepresentativebiologicalfluids(usuallyserumorplasma). 2.14SeriousAdverseEventorReaction:Anadverseeventorreactionwhichresultsindeath,is life-threatening,requiresinpatienthospitalizationorprolongationofexistinghospitalization,leadsto persistentorsignificantdisabilityorincapacity,orisacongenitalanomaly,orwhichrequiresmedical orsurgicalinterventiontopreventpotentialharmtothesubjectoranyoftheforegoingcircumstances, orwhichmayleadtodevelopmentofaddictionordrugabuse. 2.15DoubleDummyDesign:Ablindingmethodusedformaskingtheproduct(s)receivedbyeachof thestudyarmsinclinicaltrialsforcomparingtwodifferentpharmaceuticalformsofaninvestigational product,e.g.onegroupreceivingplacebotabletandactiveampoule,andtheothergroupreceiving activetabletandplaceboampoule. 2.16Multi-CenterClinicalTrial:Aclinicaltrialconductedaccordingtoasingleprotocolbutat morethanonesiteand,therefore,carriedoutbymorethanoneinvestigator. 2.17Inspection:AnactbytheAgencyofinvestigatingnaturalorlegalpersonsinvolvedinclinical trial,investigationalsiteswhereclinicaltrialsareconducted,clinicaltrial-relatedactivitiesandrecords ofserviceproviders,includingsponsororitslegalrepresentative,ifapplicable,andotherassignees, qualityassurancearrangementsandanypertinentorganizations,committeesorinstitutions,including ethicscommittees,forcompliancewiththisrequirementsofthisRegulationandotherapplicable legislation. 2.18InspectionReport:Areportissuedbythehealthauthorityconcerned,detailingtheoutcomeof inspection. 2.19Sponsor:Anindividual,institutionororganizationwhichtakesresponsibilityfortheinitiation, conductorfundingofaclinicaltrial. 2.20DirectAccess:Permissiontoexamine,analyze,verify,andreproduceanyrecordsandreportsto evaluateofaclinicaltrial.Anypartywithdirectaccess,e.g.theMinistryofHealthanditssubordinate organs,TurkishMedicinesandMedicalDevicesAgency,relevanthealthauthoritiesandauditors, shouldtakeallreasonableprecautionswithintheconstraintsoftheapplicableregulatoryrequirements tomaintaintheconfidentialityofsubjects'identitiesandsponsor’sproprietaryinformation. 2.21Documentation:Anydocuments,includingwritten,electronic,magnetic,andopticalrecords, andscans,x-rays,andelectrocardiograms,thatdescribeorrecordthemethods,conductorresultsofa clinicaltrial,thefactorsaffectingtheclinicaltrial,andtheactionstaken. 2.22EthicsCommittee:Anindependentclinicaltrialethicscommitteeorbioavailabilityand bioequivalenceethicscommittee,assembledandapprovedbytheAgencytoprovideitsscientificand ethicalopinionontheeligibilityofnaturalorlegalpersonsinvolvedinaclinicaltrial,investigational sites,informationanddocumentsthatmustbeincludedintheclinicaltrialapplicationdossier,andthe methodologiesandmaterialstobeusedforobtaininganddocumentinginformedconsentofsubjects. 2.23VulnerablePopulation:Agroupofsubjectswithlimitedorreducedautonomy,whoaresubject toaspecifichierarchyorwhoseabilitytoprotectthemselvesisyetunderdeveloped,reducedor otherwisenon-existentduetovariouseconomic,socialormedicalreasons.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 4of34 2.24EssentialDocuments:Documentswhichindividuallyandcollectivelypermitevaluationofthe conductofastudyandthequalityofthedataproduced. 2.25Confidentiality:Preventionofdisclosure,tootherthanauthorizedindividuals,ofasponsor's proprietaryinformationorofasubject'sidentity. 2.26Subject:Anindividualwhoparticipatesinaclinicaltrialbasedontheirownconsentorthatof theirlegalrepresentative,giveninwriting,inaccordancewiththisRegulationandotherapplicable legislation. 2.27SubjectIdentificationCode:Auniqueidentifierassignedbytheprincipalinvestigatoror investigatorstoeachtrialsubjecttoprotectthesubject'sidentityandusedinlieuofthesubject'sname whentheinvestigatorreportsadverseeventsand/orothertrialrelateddata. 2.27Administrativeliaison:Anindividual,preferablyholdingagraduateordoctoraldegree,who willberesponsibleforadministrativeaspectsofamulti-centerclinicaltrial,andforthecoordination betweentheprincipalinvestigatorsandethicscommittees,thesponsoror,whereappropriate,the Agencyduringconductofaclinicaltrial. 2.28GoodClinicalPractice(GCP):Asetofrulesgoverningvariousaspectsofclinicaltrialto ensureinternationally-recognizedethicalandscientificstandardsareobserved,includingindesigning, conducting,monitoring,budgeting,evaluatingandreportingclinicaltrials,andinensuringthatthe rights,privacyandbodilyintegrityofsubjectsareprotected,andthedatageneratedintheclinicaltrial arereliable,whichmustbefollowedbyallpartiesinvolvedinaclinicaltrial. 2.30Authorization(byTurkishMedicinesandMedicalDevicesAgency):Favorableopinionof TurkishMedicinesandMedicalDevicesAgencythataclinicaltrialmaybeconductedattheproposed investigationalsiteswithintheconfinesofgoodclinicalpracticeandtheapplicableregulatory requirements. 2.31Monitoring:Asetofactivitiesdesignedtooverseetheconductofaclinicaltrial,toensurethatit isconducted,recordedandreportedoninlinewiththeclinicaltrialprotocol,standardoperating procedures,goodclinicalpracticeandapplicableregulatoryrequirements. 2.32MonitoringReport:Awrittenreportfromthemonitortothesponsoraftereachsitevisitor othertrial-relatedcommunicationwiththepartiesconcernedaccordingtothesponsor’sstandard operatingprocedures. 2.33QualityAssurance:Thewholeofplannedandsystematicactionsthatareestablishedtoensure thatthetrialisperformedandthedataaregenerated,documented,recorded,andreportedin compliancewithgoodclinicalpracticeandtheapplicableregulatoryrequirements. 2.34QualityControl:Theoperationaltechniquesandactivitiesundertakenwithinthequality assurancesystemtoverifythattherequirementsforqualityofthetrial-relatedactivitieshavebeen fulfilled. 2.35LegalRepresentative:Anindividualwhohasbeenauthorizedtoconsenttoparticipationofa potentialsubjectinaclinicaltrialonbehalfofthesubjectinaccordancewiththeapplicableregulatory requirements. 2.36ComparatorProduct:Aproductorplacebousedasreferenceinaclinicaltrial. 2.37SourceDocuments:Originaldocumentsincludinghospitalrecords,laboratorynotes, memoranda,subjects'diariesorevaluationchecklists,drugdispensingrecords,recordeddatafrom automatedinstruments,copiesortranscriptionscertifiedafterverificationasbeingaccuratecopies, photographicnegatives,microfilms,x-rays,andrecordskeptatthelaboratoriesandmedico-technical departmentsinvolvedintheclinicaltrial.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 5of34 2.38SourceData:Allinformationinoriginalrecordsandcertifiedcopiesoforiginalrecordsof clinicalfindings,observations,orotheractivitiesrelevanttoaclinicaltrial.Sourcedataarecontained insourcedocuments. 2.39ClinicalTrial:Aclinicaltrial,bioavailabilitystudyorbioequivalencestudyofahuman medicinalproduct. 2.40InterimClinicalTrialReport:Areportofintermediateresultsandtheirevaluationbasedon analysesperformedduringthecourseofatrial. 2.41ClinicalTrialReport:Awrittendescriptionofastudyconductedfortherapeutic,prophylactic, ordiagnosticpurposesinhumansubjects,inwhichtheclinicalandstatisticaldescription, presentations,andanalysesarefullyintegratedintoasinglereport. 2.42Non-ClinicalStudy:Abiomedicalstudynotperformedinhumansubjects. 2.43Coordinator:Aphysicianoradentistselectedamongprincipalinvestigatorsinamulti-center clinicaltrialtoensurecoordinationbetweenprincipalinvestigatorsandethicscommittees,thesponsor, thelegalrepresentative,ifapplicable,andtheAgency,whereappropriate. 2.44Blinding(Masking):Aprocedureinwhichoneormorepartiestothetrial,suchastheprincipal investigatorortheinvestigator,subjectsormonitors,arekeptunawareoftheassignmentof investigationalproducts.Single-blindingusuallyreferstothesubjects’beingunaware,anddouble- blindingusuallyreferstothesubjects’,investigators’,monitors’,and,insomecases,dataanalysts’ beingunawareofthetreatmentassignments. 2.45SiteOrganizationManagementService:Asetofservicesrelevanttotheconductofastudy, includingarrangementofclinicaltrialfilesorpreparingsubjectsforvisits,providedbyacontract researchorganizationtoinvestigationalsites,onrequestbytheprincipalinvestigatorand independentlyfromthesponsor. 2.46CaseReportForm(CRF):Aprinted,optical,orelectronicdocumentdesignedtorecorddataon eachclinicaltrialsubjectandotherinformationasrequiredbythestudyprotocol. 2.47Authorization(byEthicsCommittee):Afavorableopinionissuedbyanethicscommittee, confirmingthataclinicaltrialmaybeconductedattheproposedinvestigationalsiteswithinthe confinesofgoodclinicalpracticeandapplicableregulatoryrequirements. 2.48PrimaryEndpoint:Themostsignificantendpointprovidingprimarydatainaclinicaltrial. 2.49Randomization(RandomizedPlacement):Theprocessofassigningtrialsubjectstotreatment orcontrolgroupsusinganelementofchancetodeterminetheassignmentsinordertoreducebias. 2.50FieldAssociate:Anindividualholdingatminimumabachelorofsciencedegreepreferablyin healthsciences,designatedtoperformcriticalstudy-relatedproceduresorperformarolewithinthe confinesoftheauthorizationsgrantedtothembytheprincipalinvestigatorinconnectionwiththe clinicaltrial,attheinvestigationalsiteunderthesupervisionandoversightoftheprincipalinvestigator. 2.51SecondaryEndpoint:Anendpointwhichislesssignificantthantheprimaryendpointina clinicaltrial. 2.52Endpoint:Avariablerepresentingakeyareaofinterestinaclinicaltrial,whichmayberelated toefficacyorsafety.Itmaybeusedsynonymouslytomeanefficacyvariabilityorsafetyvariability, butnotdemographicvariability.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 6of34 2.53PrincipalInvestigator:Aphysicianordentist,holdingagraduateordoctoraldegreeinthe disciplineconcerned,whoisresponsibleforconductofaclinicaltrialataninvestigationalsite. 2.54Contract:Awritten,signedanddatedagreementbetweentwoormorepartiestoestablish transferorassignmentofworkor,whereappropriate,financialarrangements.Thestudyprotocolmay providethebasisforacontract. 2.55ContractResearchOrganization(CRO):Anindependentorganizationoperatingaccordingto goodclinicalpracticetowhomthesponsorhasdelegatedallorsomeofitsdutiesandpowersin connectionwiththeclinicaltrialbyawrittencontract. 2.56StandardOperatingProcedures(SOPs):Detailed,writteninstructionstoproviderelevant guidanceandsupportinlinewithgoodclinicalpractice. 2.57ImpartialWitness:Aperson,whoisindependentofthetrial,whocannotbeunfairlyinfluenced bypeopleinvolvedwiththetrial,whoattendstheinformedconsentprocessifthesubjectorthe subject’slegalrepresentativecannotread,andwhoreadstheinformedconsentformandanyother writteninformationsuppliedtothesubjectaspartoftheprocessofinformingthesubjects. 2.58AuxiliaryClinicalTrialStaff:Membersofthestudyteamwhoarenotaphysicianoradentist andwhohavebeendesignatedbytheprincipalinvestigatororthesponsortofulfillspecifictasksor proceduresrelatedtotheclinicaltrialunderthesupervisionandoversightoftheprincipalinvestigator. 2.59Audit:Asystematicandindependentexaminationoftrialrelatedactivitiesanddocumentsto determinewhethertheevaluatedtrialrelatedactivitieswereconducted,andthedatawererecorded, analyzedandaccuratelyreportedaccordingtotheprotocol,sponsor'sstandardoperatingprocedures, goodclinicalpractice,andtheapplicableregulatoryrequirements. 2.60AuditTrail:Documentationthatdepictsthecourseofevents. 2.61AuditCertificate:Adocumentissuedbytheauditor,confirmingthatanaudithastakenplace. 2.62AuditReport:Awrittenevaluationbytheauditorastotheresultsoftheaudit. 3.PRINCIPLESOFGOODCLINICALPRACTICE Essentialprinciplesofgoodclinicalpracticeincludethefollowing: 3.1Clinicaltrialsshouldbeconductedinaccordancewithethicalguidelines,thegoodclinicalpractice asdescribedintheDeclarationofHelsinki,andtheapplicableregulatoryrequirements. 3.2Beforeatrialisinitiated,foreseeablerisksshouldbeweighedagainsttheanticipatedbenefitfor theclinicaltrialsubjectandsociety.Atrialshouldbeinitiatedandcontinuedonlyiftheanticipated benefitsoutweightherisks. 3.3Thewellbeing,rightsandsafetyoftheclinicaltrialsubjectsarethemostimportantconsiderations andshouldprevailoverinterestsofscienceandsociety. 3.4Theavailablenonclinicalandclinicalinformationonaninvestigationalproductshouldbe adequatetosupporttheproposedclinicaltrial. 3.5Clinicaltrialsshouldbescientificallysound,inconformancetoscientificprinciples,anddescribed inaclear,detailedprotocol. 3.6Aclinicaltrialshouldbeconductedincompliancewiththeapprovedstudyprotocol. 3.7Themedicalcaregivento,andmedicaldecisionsmadeonbehalfof,subjectsshouldalwaysbethe responsibilityofaqualifiedphysicianor,whenappropriate,ofaqualifieddentist.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 7of34 3.8Eachindividualinvolvedinconductingatrialshouldbequalifiedbyeducation,training,and experiencetoperformtheirrespectivetasks. 3.9Freelygiveninformedconsentshouldbeobtainedfromeverysubjectpriortoclinicaltrial participationinlinewiththeapplicableregulatoryrequirements. 3.10Allclinicaltrialinformationshouldberecorded,handled,andstoredinawaythatallowsits accuratereporting,interpretationandverification. 3.11Theconfidentialityofrecordsthatcouldidentifysubjectsshouldbeprotected,respectingthe privacyandconfidentialityrulesinaccordancewiththeapplicableregulatoryrequirements. 3.12Investigationalproductsshouldbemanufactured,handled,andstoredinaccordancewithgood manufacturingpracticeperapplicableregulatoryguidelines.Theyshouldbeusedinaccordancewith theapprovedprotocol. 3.13Qualitysystemsthatassurethequalityofeveryaspectofthetrialshouldbeimplemented. 4.ETHICSCOMMITTEE 4.1Theethicscommitteemembersshouldpossessthequalificationstoreviewandevaluatethe scientific,medicalandethicalaspectsoftheproposedclinicaltrial. 4.2Theethicscommitteeshouldcomprisenotlessthansevenandnotmorethanfifteenprincipal members,andalternativemembersnotfewerthanthenumberofprincipalmembers,includingatleast onenon-healthcareprofessionalandonejurist,andhealthcareprofessionals,themajorityofwhom mustbespecializedinabranchofmedicineorholdadoctoraldegreeinmedicine. 4.3Beforejoininganethicscommittee,allmembersmustreceiveanddocumenthavingreceivedbasic trainingingoodclinicalpracticeandclinicalresearchinlinewiththeapplicableregulatory requirements. 4.4Thesexdistributionofmembersisexpectedtohaveparity,ascloseaspossible,whenformingan ethicscommittee. 4.5Theethicscommitteeshouldupholdthewellbeing,rightsandsafetyofclinicaltrialsubjects,and takeparticularcarewithstudieswhichinvolvevulnerablepopulations. 4.6Theethicscommitteeshouldtakecaretoensurethattherequisiteinformationanddocumentsthat mustbeincludedinanapplicationareconformanttotheapplicableregulatoryrequirementsand submittedwithoutanyomissions. 4.7Theethicscommitteeshouldcompletereviewofaproposedclinicaltrialandnotifytheapplicant ofitsdecisionwithintheregulatorydeadlines. 4.8Whencommunicatingitsdecision,theethicscommitteeshouldincludethefollowingelements, ensurethattheformatofcommunicationconformstothetemplateprovidedontheofficialwebsiteof TurkishMedicinesandMedicalDevicesAgency,anddocumentthesameinwriting: 4.8.1Fullnameoftheclinicaltrial, 4.8.2Alistofthedocumentsreviewed,includingdateandversionnumber,ifavailable, 4.8.3Alistofethicscommitteemembers,specifyingthespecialtyofeach, 4.8.4Ifthedecisionisfavorable,thefavorabledecisionanditsdate, 4.8.5Ifthedecisionunfavorable,theunfavorabledecision,thegroundsofthedecision,anditsdate, 4.8.6Ifapreviousfavorabledecisionisbeingwithdrawnorsuspended,thegroundsforthedecision anditsdate, 4.9Theethicscommitteeshouldreviewthequalificationsoftheprincipalinvestigatorand,where appropriate,oftheinvestigator,thecoordinatorandtheadministrativeliaison,basedontheircurricula vitaeorotherdocumentsrequested.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 8of34 4.10Theethicscommitteemayrequestadditionalinformation,beyondthatprovidedonthesubject’s informedconsentform,ifitbelievesdoingsowouldmeaningfullybenefittherights,safetyand wellbeingoftheclinicaltrialsubjects. 4.11Whereanon-therapeuticstudyistobeconductedwiththeconsentofasubject’slegal representative,theethicscommitteeshouldtakeparticularcarewithdeterminingwhethertheproposed studyprotocolorotherdocumentsadequatelyaddressethicalconcernsandmeettheapplicable regulatoryrequirementsforthestudyconcerned. 4.12Wherethestudyprotocolindicatesthatobtainingpriorconsentfromthesubjectortheirlegal representativemaybenotpossibleinsituationswarrantingurgentmedicalcare,duetothesubject’s beingunconsciousortheirlegalrepresentativebeingabsentatthetimeofurgentmedicalintervention, theethicscommitteeshoulddeterminethattheproposedprotocolorotherdocumentsadequately addressrelevantethicalconcernsandmeettheapplicableregulatoryrequirements. 4.13Theethicscommitteeshouldreviewboththeamountandmethodofpaymenttosubjects, providedtocovertravel,mealsorsimilarincidentalexpensesassociatedwithparticipatinginthestudy, toassurethatneitherresultsincoercionorundueinfluenceontheclinicaltrialsubjects.Paymentstoa subjectshouldnotbeentirelycontingentoncompletionofthetrialbythesubject. 4.14Theethicscommitteemayrequestadditionalinformationonassignmentofpaymentstoclinical trialsubjects,whereappropriate. 4.15Theethicscommitteeshouldensurethatinformationoncompensationofexpensesincurredby clinicaltrialsubjects,includingtravelormeals,arespecifiedonthesubject’sinformedconsentform andotherdocumentsprovidedtotheclinicaltrialsubjects. 4.16Theethicscommitteeshouldreviewandreevaluateongoingclinicaltrialsinspecifiedintervals basedonprogressreportsandotherrelevantinformationanddocuments,takingaccountofthedegree ofrisktoclinicaltrialsubjects. 4.17Theethicscommitteewillreviewclinicaltrialapplicationsinitiallyandonanongoingbasis. 4.18Themembersoftheethicscommitteemustcomplywithconfidentialityrequirementsforany informationprovidedtothem. 4.19Themembersoftheethicscommitteeareprohibitedfromdisclosinganyinformationor documentsmadeavailabletotheminconnectionwithatrial,totheextentthatsuchinformationand documentsmaybedivulgedtoauthorizedindividualsonrequestbylegally-authorizedpartiesor officialauthorities. 4.20Themembersoftheethicscommitteewillsignanondisclosureagreementandadeclarationof absenceofconflictofinterest,preparedbyTurkishMedicinesandMedicalDevicesAgencyand postedontheAgency’sofficialwebsite,beforestartingintheirrole.Thesedocumentwillberenewed everyJanuary,orintheeventofachangetherein,andtherenewedversionwillbeforwardedto TurkishMedicinesandMedicalDevicesAgency. 4.21Toensurestandardizedoperationofethicscommittees,TurkishMedicinesandMedicalDevices AgencywillestablishstandardoperatingproceduresandpostthemontheAgency’sofficialwebsite. Theethicscommitteemustconducttheiroperationswithintheconfinesofsuchstandards. 4.22Theethicscommitteemustcomplywiththeapplicableregulatoryrequirements,goodclinical practiceandstandardoperatingprocedures,andmaintainadocumentedrecordofitsoperations. 4.23Theethicscommitteemay,whennecessary,consulttheviewofsubjectmatterexpertsonspecific issuesandinvitethemtoattendameetinginadvisorcapacity.Suchadvisorsmustalsosignthe nondisclosureagreementanddeclarationofabsenceofconflictofinterestasissuedbyTurkish MedicinesandMedicalDevicesAgencyandpostedontheAgency’sofficialwebsite.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 9of34 4.24Onlythosemembersoftheethicscommitteewhoparticipateinethicscommitteereviewand discussionsmayvote,expresstheirviewormakearecommendation. 4.25Membersoftheethicscommitteemayonlyparticipateinvotingorexpresstheirviewsiftheyare unaffiliatedwiththeclinicaltrialteamorsponsorassociatedwiththeproposedclinicaltrial.Ethics committeememberswhoareaffiliatedwithorhavearoleinastudyunderreviewmaynotparticipate inethicscommitteediscussionsandvotingforthatstudy,normaytheyhavetheirsignatureunderthe ethicscommitteedecision. 4.26Thecoordinator,administrativeliaison,principalinvestigator,investigators,sponsororsponsor’s legalrepresentativemaybeinvitedtoattendanethicscommitteemeetingforconsultationonvarious aspectsofthestudy.Theymaynot,however,participateinthevotingprocedureordeclarationof decisionbytheethicscommittee. 4.27Anup-to-datelistofethicscommitteemembers,includingtheirnamesandqualifications,must bemaintained. 4.28Ethicscommitteemembersmeetwithaquorumoftwothirdsmajorityoftotalmembership,and adoptdecisionswithaquorumofabsolutemajorityoftotalmembership. 4.29Ethicscommitteemembersserveforatwo-yearterm,andanexpiringmembermaybe reappointed. 4.30Anymemberwhofailstoattendthreeconsecutivemeetings,oratotaloffivenonconsecutive meetings,willbeautomaticallyremovedfrommembership. 5.PRINCIPALINVESTIGATORANDOTHERINVESTIGATORS 5.1Thecoordinator,principalinvestigatorandtheinvestigatorshouldbequalifiedbyeducation, training,andexperiencetoensureproperconductofthetrial. 5.2TheCVsofthecoordinator,principalinvestigatorandotherinvestigatorsmustbehand-signed, up-to-dateandconformanttotheformatprovidedontheofficialwebsiteofTurkishMedicinesand MedicalDevicesAgency.Theymustprovidedocumentedevidenceoftheirpurportedqualifications uponrequestbyTurkishMedicinesandMedicalDevicesAgency,theethicscommitteeorthesponsor. 5.3Aphysicianordentistwhoholdsadegreeinthespecialtybeinginvestigatedinthestudyandwho istotakeresponsibilityforconductofthestudymaybeappointedasprincipalinvestigator.A principalinvestigatormustholdadoctoraldegreeorbespecializedinabranchofmedicine. 5.4PhaseIclinicaltrialsandbioavailability/bioequivalencestudiesshouldbeconductedbyaqualified teamwithadequatetrainingandexperienceingoodclinicalpracticeandclinicaltrials,andamedical doctorspecializedorholdingadoctoraldegreeinpharmacology. 5.5Thecoordinator,administrativeliaison,principalinvestigatorandotherinvestigatorsmustbe thoroughlyandsufficientlyfamiliarwiththeinvestigationalproductsascharacterizedinthecurrent studyprotocol,theinvestigator’sbrochureandothersourcesofinformationmadeavailablebythe sponsor. 5.6Thecoordinator,administrativeliaison,principalinvestigatorandotherinvestigatorsmustbe knowledgeableinandcomplywithgoodclinicalpractice,thecurrentversionoftheDeclarationof Helsinkiandtheapplicableregulatoryrequirements. 5.7Thecoordinator,administrativeliaison,principalinvestigatorandotherinvestigatorsmustpermit monitoringandauditingbytheethicscommitteeorthesponsor,andinspectionsbyTurkishMedicines andMedicalDevicesAgencyorotherhealthauthoritiesconcernedonallmattersrelevanttothe clinicaltrial,includingalldocumentsrelatedtothestudy. 5.8Theprincipalinvestigatormay,whereappropriate,appointinvestigators,clinicaltrialnurses,field associatesorauxiliaryclinicaltrialstafftoassistwithconductingtheclinicaltrial,providedthat TurkishMedicinesandMedicalDevicesAgencyandtheethicscommitteearedulynotifiedofsuch appointments.Alogofsuchappointmentsmustbemaintainedbytheprincipalinvestigator.Turkish MedicinesandMedicalDevicesAgencymayannulsuchappointmentswithjustification.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 10of34 5.9Theprincipalinvestigatorshouldhaveasufficientnumberofqualifiedpersonneladequatemeans toconductthestudyproperlyandsafelywithinthecontemplatedtimeframe. 5.10Theprincipalinvestigatormustsuperviseandoverseemembersoftheclinicaltrialteamwho havebeenappointedtofulfillstudy-relatedtasksinaccordancewiththeapplicableregulatory requirements. 5.11Whereservicesfromanexternalteamareusedtoassistwithstudy-relatedtasks,theprincipal investigatormustensurethattheteamconcernedisdulyqualifiedtoperformsuchtasks,andhavein placeprocedurestoassuretheintegrityofthestudy-relatedtasksperformedandthedatagenerated. 5.12Thecoordinator,administrativeliaisonandprincipalinvestigatormusthavesufficienttimeto properlyconductandconcludethestudywithinthespecifiedtimeframe.Ifjustified,anddependingon thenatureofthestudyconcerned,thecoordinator,administrativeliaison,principalinvestigatorand otherinvestigatorsmayconcurrentlyconductmultiplestudies,totheextentthatTurkishMedicines andMedicalDevicesAgencyortheethicscommitteemay,withjustification,imposerestrictionson thisaspect. 5.13Theprincipalinvestigatormustdemonstrateapotentialforrecruitingasufficientnumberof eligiblesubjectswithintheagreedrecruitmentperiod. 5.14Thecoordinator,administrativeliaisonorprincipalinvestigatormustensurethatthestudyteamis dulyinformedaboutthestudyprotocol,investigationalproductsandstudy-relatedaspects. 5.15Theresponsibilityfortakingstudy-relatedmedicalordentaldecisionslieswiththeprincipal investigatororaninvestigatorwhoisaqualifiedphysicianordentist. 5.16Theprincipalinvestigatororotherinvestigatorsandtheinvestigationalsitemustprovide adequatemedicaltosubjectsforanyadverseevents,includingclinicallysignificantlaboratoryvalues, duringorafterparticipationofthesubjectintheclinicaltrial. 5.17Theprincipalinvestigatororotherinvestigatorsmustinformthesubjectaboutanyconcurrent conditionsandotherconditionsrequiringmedicalattentionwhichoccurduringorafterthestudyand whicharenoticedbytheprincipalinvestigatororotherinvestigators. 5.18Itisrecommendedthattheprincipalinvestigatororotherinvestigatorsinformthesubject’s primaryphysicianaboutthesubject’sparticipationintheclinicaltrial,ifthesubjecthasaprimary physicianandifthesubjectagreestotheprimaryphysicianbeinginformed. 5.19Subjectsarenotobligatedtogivetheirreasonsforwithdrawingprematurelyfromaclinicaltrial. Nevertheless,theprincipalinvestigatororotherinvestigatorsmaymakeareasonableeffortto understandthereasonsforwithdrawingfromthestudy,whilerespectingthesubject’srights. 5.20Beforeinitiatingaclinicaltrial,thecoordinator,administrativeliaisonorprincipalinvestigator mustobtainethicscommitteeapprovaland,forstudiesfallingundertheapplicableregulation, authorizationfromTurkishMedicinesandMedicalDevicesAgency. 5.21Theprincipalinvestigatororotherinvestigatorsmustconducttheclinicaltrialinlinewiththe protocolapprovedbytheethicscommitteeor,inthecaseofstudiesrequiringauthorization,by TurkishMedicinesandMedicalDevicesAgency. 5.22Thecoordinator,administrativeliaisonorprincipalinvestigatorandthesponsormustsignunder thestudyprotocoltoconfirmtheiragreement. 5.23Thecoordinator,administrativeliaisonorprincipalinvestigatormaynotamendthestudy protocolwithoutreviewandwrittenapprovalbytheethicscommitteeor,inthecaseofstudies requiringauthorizationundertheapplicableregulations,byTurkishMedicinesandMedicalDevices Agency.Whereadeviationfromtheprotocolhasoccurredoranamendmenttothestudyprotocolhas beenmadetourgentlyaddressanemergingrisk,noticetotheethicscommitteeandTurkishMedicines andMedicalDevicesAgencymustbegivenattheearliestpossibility,includingtherationaleforsuch action.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 11of34 5.24Thecoordinator,administrativeliaison,principalinvestigatororotherinvestigatorsmust documentandjustifyanydeviationfromtheapprovedprotocol,andmakeitavailabletotheethics committeeandTurkishMedicinesandMedicalDevicesAgencyonrequest. 5.25Theresponsibilityforreceiving,storing,anddispensinginvestigationalproductsuponwritten requestoraccordingtothestudyprotocol,performinginventorycontrols,andhandlingand maintainingarecordofsurplusproductslieswiththeprincipalinvestigatorateachinvestigationalsite. Theprincipalinvestigatormay,preferably,delegatethesetaskstoapharmacist. 5.26Theindividualdesignatedbytheprincipalinvestigatorshouldmaintainrecordsoftheproduct's inventoryatthesite,theusebyeachsubject,andthereturntothesponsororalternativedispositionof unusedproducts.Theserecordsshouldincludedates,quantities,batch/serialnumbers,expirationdates, andtheidentifiersassignedtotheinvestigationalproductsandtrialsubjects. 5.27Theprincipalinvestigator’sdesigneeshouldensurethattheinvestigationalproductsarestoredin linewiththeapplicableregulatoryrequirements. 5.28Theprincipalinvestigatororotherinvestigatorsshouldmaintainrecordsthatadequately documentthatthesubjectswereprovidedthedosesspecifiedbytheprotocolandreconcileall investigationalproductsreceivedfromthesponsorwiththeconsumedquantities. 5.29Theprincipalinvestigatororotherinvestigatorsshouldensurethattheinvestigationalproducts areusedonlyinaccordancewiththeapprovedprotocol. 5.30Theprincipalinvestigatororotherinvestigators,oraqualifiedpersondesignatedbytheprincipal investigator,shouldexplainthecorrectuseoftheinvestigationalproductstoeachsubjectandshould checkatsuitableintervalsthateachsubjectisfollowingtheinstructionsproperly. 5.31Theprincipalinvestigatorshouldfollowtheclinicaltrial'srandomizationprocedures,ifany,and shouldensurethatthecodeisbrokenonlyinaccordancewiththeprotocol.Forablindedtrial,the investigatorshouldpromptlydocumentandexplaintothesponsoranyprematureunblinding. 5.32Inobtaininganddocumentinginformedconsentontheform,theprincipleinvestigatororother investigators,whomustbeaphysicianordentist,shouldcomplywiththeapplicableregulatory requirementsandtheethicalprinciples. 5.33Priortobeginningofthestudy,thecoordinator,administrativeliaisonandprincipalinvestigator mustensurethattheinformedconsentofclinicaltrialsubjectshasbeendulyreceivedontheform. 5.34Theprincipleinvestigatorshouldmaintainahand-signedcopyofallinformedconsentformsin theirrecords. 5.35Theprincipalinvestigatormustensurethatthesponsorreceivesallreportabledataaccurately, withoutanyomissions,andontime,throughcasereportformsandotheressentialreports. 5.36Datareportedonthecasereportformthatarederivedfromsourcedocumentsshouldbe consistentwiththesourcedocuments,andanydiscrepanciesmustbeexplained. 5.37Anychangeorcorrectiontoacasereportformshouldbedated,initialed,andexplained.The originalentrymustnotbeobscuredandthesameshouldapplytobothwrittenandelectronicchanges orcorrections.Thesponsorshouldprovideguidancetotheprincipalinvestigatorortheinvestigator designatedbytheprincipalinvestigatoronmakingsuchcorrections.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 12of34 Thesponsorshouldhavewrittenproceduresinplacetoassurethatchangesorcorrectionsincase reportformsaredocumented,arenecessary,andareendorsedbytheprincipalinvestigatororother investigators.Theprincipalinvestigatorshouldretainrecordsofthechangesandcorrections. 5.38Thecoordinatorortheprincipalinvestigatorshouldmaintaintrialdocumentsandaccurateand sensitivesourcedata,includingallobservationsrelatedtoclinicaltrialsubjectsateachinvestigational site.Thesourcedatashouldbeattributable,legible,original,accurateandcomplete.Anychangesin thesourcedatamustnotobscuretheoriginalentrytoensuretraceability,andexplainedwhererequired. 5.39Theprincipalinvestigatorshouldmaintainclinicaltrialdocumentsinlinewiththeapplicable regulatoryrequirements,andhaveinplacemeasurestopreventaccidentalorprematuredestructionof thesedocuments. 5.40Clinicaltrialdocumentsshouldberetainedfornotlessthanfouryearsaftercompletionofthe clinicaltrialatallinvestigationalsites.However,alongerretentionperiodmaybeappliedifprovided inanagreementwiththesponsor.Itistheresponsibilityofthesponsortoinformtheprincipal investigatorwhentheretentionperiodhasended. 5.41Thefinancialaspectsoftheclinicaltrialshouldbedocumentedinanagreementbetweenthe sponsorandtheprincipalinvestigator,whichmayneedtobealsoexecutedwiththecoordinatoror administrativeliaison. 5.42Thecoordinator,administrativeliaisonorprincipalinvestigatormustensurethatmonitors, auditors,theethicscommitteeorTurkishMedicinesandMedicalDevicesAgencyorotherrelevant healthauthoritiesandinspectorshavedirectaccesstotheclinicaltrialrecords. 5.43Thecoordinator,administrativeliaisonorprincipalinvestigatorshouldprovidewritten summariesoftheclinicaltrial’sstatustotheinstitutionhostingtheclinicaltrial,theethicscommittee andTurkishMedicinesandMedicalDevicesAgency,atleastonceayearor,ifsorequestedbythe ethicscommitteeandTurkishMedicinesandMedicalDevicesAgency,inshorterintervals. 5.44Thecoordinator,administrativeliaisonorprincipalinvestigatorshouldpromptlyprovidewritten reportstothesponsor,theethicscommitteeandTurkishMedicinesandMedicalDevicesAgencyon anychangessignificantlyaffectingtheconductofthetrial,orincreasingtherisktosubjects. 5.45Thecoordinator,administrativeliaisonorprincipalinvestigatorshouldinformallconcerned partiesaboutemergingnewinformationthatmayunfavorablyimpactonthesubjects’wellbeingor conductoftheclinicaltrial. 5.46Theprincipalinvestigatororotherinvestigatorsmustcomplywiththeregulatorydeadlinesfor reportingandfulfilltheirobligations. 5.47Theprincipalinvestigatororotherinvestigatordesignatedbytheprincipalinvestigatormust immediatelyreportallseriousadverseeventstothesponsorexceptthosethattheprotocolor investigator’sbrochureidentifiesasnotneedingimmediatereporting.Theimmediatereportsshould befollowedpromptlybydetailed,writtenreports.Theimmediateandfollow-upreportsshould identifysubjectsbyuniqueidentifiersassignedtothetrialsubjects;thesubjects'names,personal identificationoraddressesmustnotbedivulged. 5.48Adverseeventsorlaboratoryabnormalitiesidentifiedintheprotocolascriticaltosafety evaluationsshouldbereportedtothesponsorbytheprincipalinvestigatorortheirdesignee,according tothereportingrequirementsandwithinthetimeperiodsspecifiedintheprotocol.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 13of34 5.49Fordeaths,theprincipalinvestigatorshouldsupplyanyadditionalinformationrequestedbythe ethicscommitteeorTurkishMedicinesandMedicalDevicesAgency,includingautopsyreportsand medicalreportsrelatedtomortalities. 5.50Ifthetrialisprematurelyterminatedorsuspendedforanyreason,theprincipalinvestigator shouldpromptlyinformtheclinicaltrialsubjects,andensureappropriatetherapyandfollow-up. 5.51Iftheinvestigatorterminatesorsuspendsaclinicaltrialwithoutpriorapprovalofthesponsor,the principalinvestigatorshouldimmediatelyinformtheinstitutionhostingtheclinicaltrial,thesponsor andtheethicscommittee,andsubmitadetailedexplanationinwritingtothesponsor,theethics committeeandTurkishMedicinesandMedicalDevicesAgency. 5.52Ifthesponsor,theethicscommitteeorTurkishMedicinesandMedicalDevicesAgency terminatesorsuspendstheclinicaltrial,thecoordinator,administrativeliaisonortheprincipal investigatorshouldinformtheinstitutionhostingtheclinicaltrial,withanexplanationofthereasons therefor. 5.53Aftercompletionoftheclinicaltrial,theprincipalinvestigatorshouldensurethattheinstitution hostingtheclinicaltrial,theethicscommitteeandTurkishMedicinesandMedicalDevicesAgencyare dulynotified. 5.54Allreferencestotheprincipalinvestigatorinthisguidelinealsoincludesthecoordinator. 6.SPONSOR 6.1Thesponsorisresponsibleforestablishingstandardoperatingprocedures,andimplementingand maintainingqualityassuranceandqualitycontrolsystemstoensurethattheclinicaltrialisconducted anddataaregenerated,documented,recorded,andreportedincompliancewiththestudyprotocol,the currentversionoftheDeclarationofHelsinki,goodclinicalpracticeandtheapplicableregulatory requirements. 6.2Thesponsorisresponsibleforsecuringagreementfromallinvolvedpartiestoensuredirectaccess toalltrialrelatedsites,sourcedataanddocumentsforthepurposeofinspectionbyTurkishMedicines andMedicalDevicesAgencyandotherrelevanthealthauthorities. 6.3Thesponsormustensurethatdirectaccesstosourcedatafromtheclinicaltrialtofacilitate monitoring,auditingandinspectionisprovidedforinthestudyprotocolorotherwrittenagreements. 6.4Qualitycontrolshouldbeappliedateachstageofdatahandlingtoensurethatalldataarereliable andhavebeenprocessedcorrectly. 6.5Thesponsorshouldhaveinplaceasystemtomanagequalitythroughoutdesign,conduct, recording,assessment,reportingandarchivingstagesoftheclinicaltrial. 6.6Thesponsorshouldfocusonclinicaltrialactivitiesessentialtoensuringprotectionofclinicaltrial subjectsandthereliabilityofthestudyresults.Qualitymanagementincludesthedesignofclinical trialprotocolsandtoolsandproceduresfordatacollectionandprocessing,aswellasthecollectionof informationthatisessentialtodecisionmaking. 6.7Themethodsusedtoassureandcontrolthequalityoftheclinicaltrialshouldbeproportionateto therisksinherentinthetrialandtheimportanceoftheinformationcollected.Thesponsorshould ensurethatallaspectsofthetrialareoperationallyfeasibleandshouldavoidunnecessarycomplexity, procedures,anddatacollection.Protocols,casereportforms,andotheroperationaldocumentsshould beclear,concise,andconsistent. 6.8Allagreementsbetweenthesponsorandprincipalinvestigatorsandotherpartiesinvolvesinthe clinicaltrialmustbeapartoftheclinicaltrialprotocol,orexecutedinwritingasseparateagreements.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 14of34 6.9Thesponsormaytransferanyorallofitstrial-relateddutiestoacontractresearchorganization, buttheultimateresponsibilityforthequalityandintegrityofthetrialdataalwaysresideswiththe sponsor.Thecontractresearchorganizationshouldimplementqualityassuranceandqualitycontrol systems. 6.10Anytrial-relateddutiesorfunctionsthathavebeentransferredtoandassumedbyacontract researchorganizationmustbespecifiedinwriting. 6.11Thesponsorshouldensureoversightofanytrial-relateddutiesandfunctionscarriedoutonits behalf. 6.12Anytrial-relateddutiesandfunctionsnotspecificallytransferredtoandassumedbyacontract researchorganizationareretainedbythesponsor. 6.13Allreferencestothesponsorinthisguidelinealsoapplytothecontractresearchorganizationto theextentthatthecontractresearchorganizationhasassumedthetrialrelateddutiesandfunctionsof thesponsor. 6.14Thesponsorshouldutilizequalifiedindividualsasappropriate,throughoutallstagesofthetrial process,fromdesigningtheprotocolandcasereportformsandplanningtheanalysestoanalyzingand preparinginterimandfinalclinicaltrialreports. 6.15Thesponsorshouldworkwithqualifiedmedicalstaffwhoareableandpreparedtorespondto anyquestionsorconcernsrelatedtotheclinicaltrial.Externalconsultantsmaybeusedforthis purpose,whereappropriate. 6.16Thesponsorshouldutilizeappropriatelyqualifiedindividualstosupervisetheoverallconductof thetrial,tohandlethedata,toverifythedata,toconductthestatisticalanalyses,andtopreparethe trialreports. 6.17Thesponsormayestablishanindependentdatamonitoringcommitteetoassesstheprogressofa clinicaltrial,includingthesafetydataandthecriticalefficacyendpointsatintervals,andto recommendtothesponsorwhethertocontinue,modify,orstopatrial.Theindependentdata monitoringcommitteeshouldhaveinplaceoperatingproceduresandmaintainwrittenrecordsofall itsmeetings. 6.18Whereappropriate,theethicscommitteeorTurkishMedicinesandMedicalDevicesAgencymay requirethesponsortoestablishanindependentdatamonitoringcommittee. 6.19Whenusingelectronictrialdatahandlingorremoteelectronictrialdatasystems,thesponsor should: 6.19.1Ensureanddocumentthattheelectronicdataprocessingsystemsconformtothesponsor’s establishedvalidationrequirementsforcompleteness,accuracy,reliability,andconsistentintended performance; 6.19.2Maintainstandardoperatingproceduresforthesesystems; 6.19.3Ensurethatthesystemsaredesignedtopermitdatachangesinsuchawaythatthedatachanges aredocumentedandthatthereisnodeletionofentereddata,i.e.maintainanaudittrail,datatrail,edit trail; 6.19.4Maintainasecuritysystemthatpreventsunauthorizedaccesstothedata; 6.19.5Maintainalistoftheindividualswhoareauthorizedtomakedatachanges; 6.19.6Maintainandensureadequatebackupofthedata; 6.19.7Ifdataaretransformedduringprocessing,ensurethatitisalwayspossibletocomparethe originaldataandobservationswiththeprocesseddata; 6.19.8Safeguardtheblinding,ifany.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 15of34 6.20Thesponsorshoulduseasubjectidentifierthatallowsidentificationofallthedatareportedfor eachsubject. 6.21Thesponsor,orotherownersofthedata,shouldretainallofthesponsor’sessentialdocuments pertainingtotheclinicaltrial. 6.22Thesponsorshouldretainallofthesponsor’sessentialdocumentsinconformancewiththe applicableregulatoryrequirementsofthecountrieswheretheproductisapproved,orwherethe sponsorintendstoapplyforapproval. 6.23Ifthesponsordiscontinuestheclinicaldevelopmentoftheinvestigationalproductcompletelyor partially,thesponsorshouldmaintainallstudy-relateddocumentsforatleastfourteenyearsafter formalterminationofthestudy. 6.24Ifthesponsordiscontinuestheclinicaldevelopmentoftheinvestigationalproduct,thesponsor shouldnotifyallinvestigators,theethicscommitteeandTurkishMedicinesandMedicalDevices Agency,alongwithadescriptionoftherationaleforthatdecision. 6.25AnytransferofthedatashouldbereportedtotheethicscommitteeandTurkishMedicinesand MedicalDevicesAgency,alongwithadescriptionoftherationaleforthataction. 6.26Thesponsorshouldinformtheprincipalinvestigatorinwritingoftheneedtoretaintherecordsor thatretentionoftherecordsisnolongernecessary. 6.27Thesponsorisresponsibleforselectingtheprincipalinvestigatorandotherinvestigators,andthe investigationalsiteswheretheclinicaltrialwouldbeconducted. 6.28Formulti-centertrials,theselectionofacoordinatorandanadministrativeliaisonalsolieswith thesponsor. 6.29Beforeenteringanagreementwiththecoordinator,administrativeliaison,principalinvestigator andotherinvestigatorstoconductthetrial,thesponsorshouldprovidethemtheprotocolandanup-to- dateinvestigator'sbrochure,andshouldallowthemsufficienttimetoreviewthedocuments. 6.30Thesponsorshouldreachagreementwiththecoordinator,administrativeliaison,theprincipal investigatororotherinvestigatorsontheaspectslistedbelow,andincorporatetheagreementinthe protocolorcosignanalternativeagreementforthispurpose: 6.30.1Conductingthetrialincompliancewithgoodclinicalpractice,applicableregulatory requirements,andtheclinicaltrialprotocolacceptedbythesponsor,approvedbytheethicscommittee andauthorizedbyTurkishMedicinesandMedicalDevicesAgency, 6.30.2Complyingwiththeproceduresfordatarecordingandreporting, 6.30.3Permittingmonitoring,auditingandinspection,and 6.30.4Retainingtheessentialdocumentswhichmustbemaintainedbytheprincipalinvestigatoruntil thesponsorconfirmsthatthedocumentsarenolongerneeded,forthedurationandinthemanner prescribedintheapplicableregulations. 6.31Priortoinitiatingthetrial,thesponsorshoulddefineandimplementalltrial-relateddutiesand functions. 6.32Ifrequiredbytheapplicableregulatoryrequirements,thesponsorshouldprovideinsurancewith legalandfinancialcoveragefortheprincipalinvestigatorandotherinvestigatorsagainstclaimsarising fromthetrial,andindemnifyanylossesincurred. 6.33Thesponsorshouldhavewrittenpoliciesinplace,describinghowthecostsoftreatmentoftrial- relatedinjurieswouldbecovered,inaccordancewiththeapplicableregulatoryrequirements. 6.34Wheretrialsubjectsreceivecompensation,themethodandmannerofcompensationshould complywiththeapplicableregulatoryrequirements.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 16of34 6.35Thefinancialaspectsofthetrialshouldbedocumentedinanagreementbetweenthesponsorand theprincipalinvestigator;thesameagreementshouldbealsosignedwiththecoordinatoror administrativeliaison,whereappropriate. 6.36Beforeinitiatingtheclinicaltrial,thesponsorshouldsubmitanyrequiredapplicationstoTurkish MedicinesandMedicalDevicesAgency,usingtheformatpostedontheAgency’sofficialwebsite,for review,acceptanceorpermissiontobeginthetrials.Anynotificationshouldbedatedandcontain sufficientinformationtoidentifytheprotocol. 6.37Attheinitialapplicationfortheclinicaltrial,thesponsormustcommunicatetotheethics committeeandTurkishMedicinesandMedicalDevicesAgencythenumberofclinicaltrialsubjects plannedtobeenrolledintheclinicaltrialinTürkiye,andthetotalnumberofsubjectstargetedfor enrollment.Wherethetargetedenrollmentspecifiedintheinitialapplicationcannotbeachieved,itis possibletoincreasethenumberofsubjectstobeenrolledfromTürkiye,subjecttoapprovalbythe ethicscommitteeandauthorizationbyTurkishMedicinesandMedicalDevicesAgency,basedon rationaleandupdatedversionsofessentialdocuments,includingthoserelatedtoinsuranceand budgeting. 6.38Inamulti-centertrial,thesponsorshouldinformtheinvestigationalsitesthatthestudywouldbe alsoconductedatotherinvestigationalsites.Thenotificationshouldbeappendedwithacopyofthe ethicscommitteeapprovalforthestudy,letterofauthorizationbyTurkishMedicinesandMedical DevicesAgency,asummaryofthestudyprotocolandtheinformedconsentform. 6.39Whenplanningtrials,thesponsorshouldensurethatsufficientsafetyandefficacydatafrom nonclinicalstudiesorclinicaltrialsareavailabletosupporttherouteofadministration,dosages, durationofuse,andtrialpopulationtobestudied. 6.40Thesponsorshouldupdatetheinvestigator'sbrochureassignificantnewinformationbecomes available. 6.41Thesponsorshouldensurethattheinvestigationalproductischaracterizedasappropriatetothe stageofdevelopmentoftheproduct,ismanufacturedinaccordancewiththeapplicablerequirements ofgoodmanufacturingpractice,andiscodedandlabeledinamannerthatprotectstheblinding,if applicable.Inaddition,thelabelingshouldcomplywithapplicableregulatoryrequirements. 6.42Thesponsorshouldprovidetheacceptablestorageconditions,storagetimes,reconstitutionfluids andprocedures,anddevicesforinfusion,ifapplicable,fortheinvestigationalproduct,andinformall involvedparties. 6.43Thesponsorshouldensurethattheinvestigationalproductispackagedtopreventcontamination andunacceptabledeteriorationduringtransportandstorage. 6.44Inblindedtrials,thecodingsystemfortheinvestigationalproductsshouldincludeamechanism thatpermitsrapididentificationoftheproductsincaseofamedicalemergency,butdoesnotpermit breakingoftheblind. 6.45Ifsignificantformulationchangesaremadeintheinvestigationalorcomparatorproductsduring thecourseofclinicaldevelopment,theresultsofanyadditionalstudiesoftheformulatedproduct(e.g. stability,dissolutionrate,bioavailability)neededtoassesswhetherthesechangeswouldsignificantly alterthepharmacokineticprofileoftheproductshouldbeavailablepriortotheuseofthenew formulationintheclinicaltrial. 6.46Thesponsorisresponsibleforsupplyingtheprincipalinvestigatorandinvestigationalsiteswith theinvestigationalproduct. 6.47Thesponsormustnotsupplyanyinvestigationalproductstotheinvestigationalsitesuntil approvalfromtheethicscommitteeandauthorizationfromTurkishMedicinesandMedicalDevices Agencyhavebeenreceivedforinitiatingtheclinicaltrial.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 17of34 6.48Theresponsibilitylieswiththesponsortoensurethatinvestigationalproductsarestored, distributedanddeliveredtoinvestigationalsitesunderappropriateconditions,thesameconditionsare maintainedattheinvestigationalsites,andunusedproductsarepickedupfrominvestigationalsitesfor returningordestruction,ensuringthatrecordsaremaintainedofeachofthesesteps. 6.49Thesponsorshouldensurethatinstructionsthattheprincipalinvestigatorortheirdesigneemust followforthehandlingandstorageofinvestigationalproductsanddocumentationthereofarelaid downinwrittenagreements.Theproceduresshouldaddressadequateandsafereceipt,handling, storage,dispensing,retrievalofunusedproductfromsubjects,andreturnofunusedinvestigational productstothesponsororalternativelydisposedifauthorizedbythesponsorandincompliancewith theapplicableregulatoryrequirements. 6.50Thesponsorshouldensuretimelydeliveryofinvestigationalproductstotheinvestigators. 6.51Thesponsorshouldmaintainasystemforretrievinginvestigationalproductsanddocumenting thisretrieval(e.g.forretrievalofdefectiveproducts,retrievalofsurplusproductsafterconclusionof theclinicaltrial,retrievalofexpiredproducts). 6.52Thesponsorshouldmaintainasystemforthedispositionofunusedinvestigationalproductsand forthedocumentationofthisdisposition. 6.53Thesponsorshouldtakestepstoensurethattheinvestigationalproductsarestableoverthe periodofuse. 6.54Thesponsorshouldmaintainsufficientquantitiesoftheinvestigationalproductsusedinthetrials toreconfirmspecifications,shouldthisbecomenecessary,andmaintainrecordsofbatchsample analysesandcharacteristics.Becausetheregulatoryresponsibilitylieswiththemanufacturerto maintainretentionsamplesinasufficientquantitytoallowbatchanalysesofinvestigationalproducts, includingcomparators,marketedinTürkiyeandtobeprocuredlocallyforuseinthestudy,this responsibilitymaybewaivedforthesponsor. 6.55Totheextentstabilitypermits,thesponsorshouldretainsamplesataninvestigationalsiteabroad orwithinTürkiyeeitheruntiltheanalysesofthetrialdataarecompleteorasrequiredbythe applicableregulatoryrequirements,whicheverrepresentsthelongerretentionperiod. 6.56Thesponsorshouldensurethatitisspecifiedintheprotocolorotherwrittenagreementthatthe coordinator,administrativeliaison,principalinvestigatorandotherinvestigatorsprovidedirectaccess tosourcedataanddocumentsfortrial-relatedmonitoring,audits,ethicscommitteereview,and inspectionbyTurkishMedicinesandMedicalDevicesAgencyorothercompetenthealthauthorities. 6.57Thesponsorshouldverifythateachsubjecthasconsented,inwriting,todirectaccesstotheir originalmedicalrecordsfortrial-relatedmonitoring,audit,ethicscommitteereviewandinspection. 6.58Thesponsorisresponsiblefortheongoingsafetyevaluationoftheinvestigationalproducts. 6.59Thesponsorshouldpromptlynotifythecoordinator,administrativeliaison,principalinvestigator andotherinvestigators,investigationalsites,theethicscommitteeandTurkishMedicinesandMedical DevicesAgencyoffindingsthatcouldadverselyaffecttheconductofthetrialorthesafetyofsubjects, oralterthefavorableopiniontocontinuethetrial.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 18of34 6.60Thesponsorshouldexpeditethereportingofalladversedrugreactionsthatarebothseriousand unexpectedtothecoordinator,administrativeliaison,allprincipalinvestigatorsandotherinvestigators andtotheethicscommittee,whererequired,andTurkishMedicinesandMedicalDevicesAgency. 6.61ThesponsorshouldsubmittoTurkishMedicinesandMedicalDevicesAgencyallsafetyupdates andperiodicreports,asrequiredbyapplicableregulatoryrequirements. 6.62Thesponsorshouldensurepropermonitoringoftheclinicaltrial. 6.63Thesponsorshouldmonitorthestudytoensurethattherightsandwellbeingofhumansubjects areprotected;thereportedtrialdataareaccurate,complete,andverifiablefromsourcedocuments; theconductofthetrialisincompliancewiththecurrentlyapprovedstudyprotocol,goodclinical practiceandtheapplicableregulatoryrequirements. 6.64Thesponsormayconductauditing,separatelyandindependentlyfromroutinemonitoringor qualitycontrolfunctions,toverifythattheconductofthestudycomplieswiththestudyprotocol, standardoperatingprocedures,goodclinicalpracticeandtheapplicableregulatoryrequirements. 6.65Thesponsorshouldappointindividuals,whoareindependentoftheclinicaltrialsanddata collectionsystems,toconductaudits. 6.66Thesponsorshouldensurethattheauditorshavesufficienttrainingandexperiencetoconduct auditsproperly.Anauditor’squalificationsshouldbedocumented. 6.67Thesponsorshouldensurethattheauditingofclinicaltrialsandsystemsisconductedin accordancewithwrittenproceduresonwhattoaudit,howtoaudit,thefrequencyofaudits,andthe formandcontentofauditreports.TheauditreportsubmittedtoTurkishMedicinesandMedical DevicesAgencyorothercompetenthealthauthoritiesshouldcoverthenumberofsubjectsinthetrial, thetypeandcomplexityofthetrial,thelevelofriskstothetrialsubjects,andanyidentifiedproblems. Theobservationsandfindingsoftheauditorsshouldbedocumented.Topreservetheindependence andvalueoftheauditfunction,TurkishMedicinesandMedicalDevicesAgencyorothercompetent healthauthoritiesshouldnotroutinelyrequesttheauditreports.TurkishMedicinesandMedical DevicesAgencyorothercompetenthealthauthoritiesmayseekaccesstoanauditreportonacaseby casebasiswhenevidenceofseriousbreachesofgoodclinicalpracticeexists,orinthecourseoflegal proceedings. 6.68Noncompliancewiththeprotocol,standardoperatingprocedures,goodclinicalpracticeor applicableregulatoryrequirementsbythesponsor’sstafforbythecoordinator,administrativeliaison, principalinvestigatororotherinvestigatorsshouldleadtopromptactionbythesponsortosecure compliance. 6.69Ifthemonitoringorauditingidentifiesseriousorpersistentnoncomplianceonthepartofthe coordinator,principalinvestigatororotherinvestigatorsorotherindividualstakingpartinthestudy, thesponsorshouldterminatetheirinvolvementinthetrialandpromptlynotifytheethicscommittee andTurkishMedicinesandMedicalDevicesAgency. 6.70Ifatrialisprematurelyterminatedorsuspended,thesponsorshouldpromptlyinformthe principalinvestigator,theethicscommitteeandTurkishMedicinesandMedicalDevicesAgencyof theterminationorsuspensionandthereasonstherefor. 6.71Whetherthetrialiscompletedorprematurelyterminated,thesponsorshouldensurethatthe clinicaltrialreportsarepreparedandprovidedtotheethicscommitteeandTurkishMedicinesand MedicalDevicesAgency. 6.72Formulti-centerstudies,thesponsorshouldensurethatthecasereportformsaredesignedto capturetherequireddataatallinvestigationalsites,andforthoseinvestigatorswhoarecollecting additionaldata,supplementalcasereportformsareprovided,whicharedesignedtocapturethe additionaldata.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 19of34 6.73Theresponsibilitiesofthecoordinator,administrativeliaison,principalinvestigatorsandothers participatingintheclinicaltrialshouldbedocumentedbythesponsorpriortothestartofthetrial. 6.74Thesponsorshouldensurethatthecoordinator,principalinvestigatorsandotherinvestigatorsare giveninstructionsonfollowingtheprotocol,oncomplyingwithauniformsetofstandardsforthe assessmentofclinicalandlaboratoryfindings,andoncompletingthecasereportforms,andmaintain recordsoftheseinstructions. 6.75Thesponsorshouldfacilitatecommunicationbetweentheprincipalinvestigator,coordinator, administrativeliaison,otherinvestigatorsandotherstakingpartinthestudy. 6.76Thesponsorshouldensurethatthestudyisproperlymonitored. 6.77Theresponsibilitiesofthesponsorandothersinvolvedintheclinicaltrialregardinguseof computerizedsystemsshouldbeclear,andthesponsorshouldprovidetrainingtousersonhowto properlyusethesystems. 6.78Forchangesinthecomputerizedsystems,includingsoftwareupdatesordatatransfers,the sponsorshouldensuretheintegrityofthedataincludinganydatathatdescribethecontext,content andstructure. 6.79Thesponsorshoulduseasystematic,prioritizedandrisk-basedapproachtomonitoringclinical trials. 7.QUALITYMANAGEMENT 7.1.Allpartiesinvolvedinthetrialteamareresponsiblefortheestablishmentandimplementation ofaqualitymanagementsystemwithintheconfinesoftheirrolesandauthorizationsaslaiddownin thisGuideline. 7.2Thequalitymanagementsystemshouldusearisk-basedapproachasdescribedbelow: 7.2.1Duringprotocoldevelopment,thesponsorshouldidentifythoseprocessesanddatathatare criticaltoassurehumansubjectprotectionandthereliabilityofstudyresults. 7.2.2Riskstocriticalstudyprocessesanddatashouldbeidentified.Risksshouldbeconsideredat boththesystemlevel(e.g.standardoperatingprocedures,computerizedsystems,personnel)and clinicaltriallevel(e.g.investigationalproduct,trialdesign,datacollectionandrecording). 7.2.3Theidentifiedrisksshouldbeevaluatedbyconsidering: 7.2.3.1Thelikelihoodoferrorsoccurring,givenexistingcontrols. 7.2.3.2Theimpactofsucherrorsonhumansubjectprotectionanddataintegrity. 7.2.3.2Theextenttowhichsucherrorswouldbedetectable. 7.2.4Thesponsorshouldidentifythoserisksthatshouldbereducedorcanbeaccepted.Risk mitigationactivitiesmaybeincorporatedinprotocoldesignandimplementation,monitoringplans, agreementsbetweenpartiesdefiningrolesandresponsibilities,systematicsafeguardstoensure adherencetostandardoperatingprocedures,andtraininginprocessesandprocedures.Predefined qualitytolerancelimitsshouldbeestablished,takingintoconsiderationthemedicalandstatistical characteristicsofthevariablesaswellasthestatisticaldesignofthetrial,toidentifysystematicissues thatcanimpactsubjectsafetyordataintegrity.Detectionofdeviationsfromthepredefinedquality tolerancelimitsshouldtriggeranevaluationtodetermineifactionisneeded. 7.2.5Thequalitymanagementactivitiesshouldbedocumentedandcommunicatedtotrial stakeholderstofacilitateriskreviewandcontinualimprovementduringclinicaltrialexecution. 7.2.6Thesponsorshouldperiodicallyreviewriskcontrolmeasurestoensuretheimplementedquality managementactivitiesremaineffectiveandrelevant,takingintoaccountemergingknowledgeand experience.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 20of34 7.2.7.Thesponsorshoulddescribethequalitymanagementapproachimplementedinthetrialand summarizeimportantdeviationsfromthepredefinedqualitytolerancelimitsintheclinicalstudy report. 8.MONITORSANDMONITORING 8.1Monitorsmustbeappointedbythesponsor. 8.2Monitorsmustbeappropriatelytrainedongoodclinicalpracticeandclinicaltrials,andmusthave thescientificorclinicalknowledgeneededtomonitorthetrialadequately. 8.3Thequalificationsofthemonitormustbedocumented. 8.4Monitorsmustbethoroughlyfamiliarwiththeinvestigationalproducts,theprotocol,written informedconsentformandanyotherwritteninformationtobeprovidedtosubjects,thesponsor's standardoperatingprocedures,goodclinicalpractice,andtheapplicableregulatoryrequirements. 8.5Thesponsormustconsiderissuessuchasthedeterminationoftheextentandnatureofmonitoring, objective,purpose,design,complexity,blinding,size,andendpointsofthetrial. 8.6On-sitemonitoringmustgenerallybecarriedoutbefore,during,andafterthetrial.Nevertheless, electronicsystemsorapplicationsmaybealsousedformonitoring,commensuratewiththenatureof theclinicaltrialandtherisksinvolved. 8.7Themonitors,inaccordancewiththesponsor'srequirements,mustcarryoutthefollowing activitieswhenrelevantandnecessarytothetrialandthetrialsite: 8.7.1Actingasthemainlineofcommunicationbetweenthecoordinator,administrativeliaison, principalinvestigatororotherinvestigators. 8.7.2Verifyingthattheprincipalinvestigatorandotherinvestigatorshaveadequatequalificationsand resourcesandremainadequatethroughoutthetrialperiod,thefacilities,includinglaboratories, equipment,andstaff,areadequatetosafelyandproperlyconductingthetrialandremainadequate throughoutthetrialperiod. 8.7.3Verifying,fortheinvestigationalproducts: 8.7.3.1thatstoragetimesandconditionsareacceptable, 8.7.3.2investigationalproductsuppliesaresufficientthroughoutthetrial, 8.7.3.3thattheinvestigationalproductsaresuppliedonlytosubjectswhoareeligibletoreceiveitand atthetrialprotocol-specifieddosesandforprotocol-specifieddurations, 8.7.3.4thatsubjectsareprovidedwithnecessaryinstructionsontheproperadministration,handling, storage,andreturnoftheinvestigationalproducts. 8.7.3.5thatthereceipt,use,andreturnoftheinvestigationalproductsattheinvestigationalsitesare controlledanddocumentedproperly, 8.7.3.6thatthedispositionofunusedinvestigationalproductsattheinvestigationalsitescomplieswith applicableregulatoryrequirements. 8.7.4Verifyingthattheprincipalinvestigatorandotherinvestigatorsfollowtheapprovedprotocoland allapprovedamendments,ifany, 8.7.5Verifyingthatthewritteninformedconsentwasobtainedfromeachsubject,beforeparticipating inthetrial, 8.7.6Ensuringthattheprincipalinvestigatorandotherinvestigatorsreceivethecurrentinvestigator’s brochure,alltrial-relateddocuments,andalltrialsuppliesneededtoconductthetrialproperlyandto complywiththeapplicableregulatoryrequirements, 8.7.7Verifyingthatthecoordinator,administrativeliaison,principalinvestigatorandother investigatorsareperformingtheirspecifiedtrialfunctionsinaccordancewiththeprotocolandany otherwrittenagreementsbetweenthesponsorandtheprincipalinvestigator,andhavenotdelegated thesefunctionstounauthorizedindividuals,

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 21of34 8.7.8Verifyingthattheprincipalinvestigatorandtheinvestigatorwhoisadoctorordentistare enrollingonlyeligiblesubjects, 8.7.9Ensuringthatthesubjectrecruitmentdateisdulynotified, 8.7.10Verifyingthatsourcedataandothertrialrecordsareaccurate,complete,keptup-to-dateand maintained, 8.7.11Verifyingthattheprincipalinvestigatorandtheinvestigatorwhoisadoctorordentistprovides alltherequiredreports,notifications,applications,andsubmissions,andthatthesedocumentsare accurate,complete,timely,legible,dated,andidentifythetrial. 8.7.12Checkingtheaccuracyandcompletenessofthecasereportform(CRF)entries,source documentsandothertrial-relatedrecordsagainsteachother. 8.8Themonitorspecificallymustverifythat: 8.8.1thedatarequiredbythetrialprotocolarereportedaccuratelyontheCRFsandareconsistentwith thesourcedata, 8.8.2anydoseortherapymodificationsarewelldocumentedforeachofthetrialsubjects, 8.8.3adverseevents,concomitantmedicationsandtemporalillnessesarereportedinaccordancewith theprotocolandtheCRFs, 8.8.4missedvisitsbysubjects,andskippedtestsandexaminationsareclearlyreportedassuchonthe CRFs, 8.8.5allwithdrawalsanddropoutsbyenrolledsubjectsfromthetrialarereportedandexplainedonthe CRFs, 8.8.6theprincipalinvestigatorandtheinvestigatorwhoisadoctorordentistareinformedofanyCRF entryerror,omission,orillegibility, 8.8.7appropriatecorrections,additions,ordeletionsaremade,dated,explained,ifnecessary,andare madebytheprincipalinvestigatororbyanotherinvestigatorwhoisauthorizedtomodifyoriginal CRFs, 8.8.8allsafetyreportsareappropriatelyreportedincompliancewithapplicableregulatory requirementstoTurkishMedicinesandMedicalDevicesAgency,theethicscommitteeandthe sponsor, 8.8.9theprincipalinvestigatorismaintainingtheessentialdocuments, 8.8.10deviationsfromthestudyprotocol,standardoperatingprocedures,GoodClinicalpractices,and theapplicableregulatoryrequirementsarecommunicatedtotheprincipalinvestigatorandappropriate actiondesignedtopreventrecurrenceofthedetecteddeviationsistaken. 8.9Themonitormustfollowthesponsor'sestablishedwrittenstandardoperatingprocedures,aswell asapplicableregulatoryrequirementsandproceduresspecifiedbytheprincipalinvestigatorfor monitoringaspecifictrial. 8.10Themonitormustsubmitawrittenreporttothesponsoraftereachvisittotheinvestigationalsite ortrial-relatedcommunication.Reportsmustincludethedate,theinvestigationalsite,thenameofthe monitor,andthenameoftheprincipalinvestigatororotherindividualscontacted.Reportsmust containasummaryofwhatthemonitorreviewedandthemonitor'sstatementsconcerningthe significantfindings,deviations,deficiencies,conclusions,actionstakenortobetakenoractions recommendedtosecurecompliance.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 22of34 8.11.Thereviewandfollow-upofthemonitoringreportbythesponsormustbedocumentedbythe sponsor'sdesignatedrepresentative. 9.CLINICALSTUDYPROTOCOLANDPROTOCOLAMENDMENTS Thecontentsofatrialprotocolmustgenerallyincludethefollowingtopics.However,sitespecific informationmaybeprovidedonseparateprotocolpages,oraddressedinaseparateagreement,and someoftheinformationlistedbelowmaybecontainedinotherdocumentsreferencedintheprotocol, suchastheinvestigator’sbrochure: 9.1Trialprotocoltitle,protocolnumber,anddate, 9.2Dateandnumberofanyprotocolamendments,whereapplicable, 9.3Nameandaddressofthesponsorandmonitor,ifotherthanthesponsor, 9.4Nameandtitleofthepersonauthorizedtosignthetrialprotocolandprotocolamendmentson behalfofthesponsor, 9.5Name,title,address,andtelephonenumbersofthesponsor'smedicalexpert,ordentistwhen appropriate,forthetrial, 9.6Nameandtitleoftheinvestigators,whoareresponsibleforconductingthetrial,andtheaddress andtelephonenumbersofthetrialsites, 9.7Name,title,address,andtelephonenumbersofthequalifiedphysicianordentist,whois responsibleforalltrial-siterelatedmedicalordentaldecisions, 9.8Addressesoftheclinicallaboratoriesandmedicalorotherdepartmentsorinstitutionsinvolvedin thetrial, 9.9Nameanddescriptionofinvestigationalproducts,ifapplicable, 9.10Asummaryoffindingsfromnonclinicalstudiesthatpotentiallyhaveclinicalsignificanceand fromclinicaltrialsthatarerelevanttothetrial, 9.11Summaryoftheknownandpotentialrisksandbenefitstosubjects, 9.12Descriptionofandjustificationfortherouteofadministration,dosage,dosageregimen,and treatmentperiods, 9.13Astatementthatthetrialwillbeconductedincompliancewiththetrialprotocol,goodclinical practiceandtheapplicableregulatoryrequirements, 9.14Adescriptionofthepopulationtobestudied, 9.15Referencestoliteratureanddatathatarerelevanttothetrialandthatprovideessential informationforthetrial, 9.16Adetaileddescriptionoftheobjectivesandthepurposeofthetrial, 9.17Thescientificintegrityofthetrialandthecredibilityofthedatafromthetrialdepend substantiallyonthetrialdesign.Adescriptionofthetrialdesignmustinclude: 9.17.1Aspecificstatementoftheprimaryendpointsandthesecondaryendpoints,ifany,tobe measuredduringthetrial, 9.17.2Adescriptionofthetypeanddesignoftrialtobeconductedandaschematicdepictionoftrial design,proceduresandstages, 9.17.3Descriptionofthemeasurestakentominimizeoravoidbias, 9.17.4Adescriptionofthetrialtreatmentsandthedosageanddosageregimenoftheinvestigational products, 9.17.5Adescriptionofthedosageform,packaging,andlabelingoftheinvestigationalproducts, 9.17.6Theexpecteddurationofsubjectparticipation,andadescriptionofdurationofalltrialperiods, includingfollow-up,ifany, 9.17.7Adescriptionofthestoppingrulesordiscontinuationcriteriaforindividualsubjects,aspartsof trialandfortheentiretrial, 9.17.8Drugaccountabilityproceduresfortheinvestigationalproduct,ifany,

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 23of34 9.17.9Maintenanceoftrialtreatmentrandomizationcodesandproceduresforbreakingcodes, 9.17.10Theidentificationofanydatatoberecordeddirectlyonthecasereportforms(i.e.noprior writtenorelectronicrecordofdata),andtobeconsideredtobesourcedata. 9.18Subjectinclusioncriteria, 9.19Subjectexclusioncriteria, 9.20Subjectwithdrawalcriteriaandproceduresspecifying: 9.20.1Whenandhowtowithdraworremovesubjectsfromthetrial, 9.20.2Thetypeandtimingofthedatatobecollectedforwithdrawnorremovedsubjects, 9.20.3Whetherandhowsubjectsaretobereplaced, 9.20.4Thefollow-upforsubjectswithdrawnorremovedfromthetrial. 9.21Thetreatmentstobeadministered,includingthename,dose,dosingscheduleandrouteof administrationforallproducts,andthetreatmentperiod,includingthefollow-upperiodsforsubjects foreachinvestigationalproducttreatment,treatmentgroupandtreatmentarminthetrial, 9.22Medicationsandtreatmentspermitted(includingrescuemedication)andnotpermittedbeforeor duringthetrial, 9.23Proceduresformonitoringsubjectcompliance, 9.24Specificationoftheefficacyparameters, 9.25Methodsandtimingforassessing,recording,andanalyzingefficacyparameters, 9.26.Assessmentofsafety: 9.26.1.Specificationofsafetyparameters, 9.26.2Themethodsandtimingforassessing,recording,andanalyzingsafetyparameters, 9.26.3Proceduresforreportingandrecordingadverseeventandtemporalillnesses, 9.26.4Thetypeanddurationofthefollow-upofsubjectsafteradverseevents. 9.27Statistics: 9.27.1Adescriptionofthestatisticalmethodstobeemployed,includingtimingofanyplanned interimanalyses, 9.27.2Thenumberofsubjectsplannedtobeenrolled. 9.27.3Inmulti-centertrials,thenumbersofenrolledsubjectsprojectedforeachinvestigationalsite, 9.27.4Reasonforchoiceofsamplesize,includingadiscussionofthepowerofthetrialandclinical justification, 9.27.5Thelevelofsignificancetobeused, 9.27.6Criteriafortheterminationofthetrial, 9.27.7Procedureforaccountingformissing,unused,andfalsedata, 9.27.8Proceduresforreportinganydeviationsfromtheoriginalstatisticalplan(anydeviationsfrom theoriginalstatisticalplanmustbedescribedandjustifiedinprotocolorinthefinalreport,as appropriate), 9.27.9Theselectionofsubjectstobeincludedintheanalyses(e.g.alleligiblesubjects,allevaluable subjects,allrandomizedsubjects,subjectswhohavereceivedtheinvestigationaldrug).

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 24of34 9.28Alistofpersonsorentitieswhohavebeengranteddirectaccesstosourcedata, 9.29Adescriptionoftheethicalconsiderationsforthetrial, 9.30Processingandrecordingthedata, 9.31Particularsregardingthefinanceandinsurance,ifnotaddressedinaseparateagreement, 9.32Publishingpolicy,ifnotaddressedinaseparateagreement. 9.33Adescriptionofthearrangementsinplacetoprovidesubjectswithpost-trialaccesstotreatments thathavebeenshowntobebeneficialduringthetrial. 10.INFORMEDCONSENTFORM 10.1Inobtaininganddocumentinginformedconsent,caremustbetakentocomplywiththe applicableregulatoryrequirements,goodclinicalpracticeandtheethicalprinciplesthathavetheir originintheDeclarationofHelsinki. 10.2Priortothebeginningofthetrial,approvalfromtheethicscommitteeandauthorizationfrom TurkishMedicinesandMedicalDevicesAgencymusthavebeenobtainedforthewritteninformed consentformwhichistobeprovidedtoclinicaltrialsubjects. 10.3Thewritteninformedconsentformtobeprovidedtosubjectsshouldberevisedwhenever importantnewinformationbecomesavailablethatmayberelevanttothesubject’sconsent.Before beingused,anyrevisedwritteninformedconsentformmustreceiveapprovalfromtheethics committeeandauthorizationfromTurkishMedicinesandMedicalDevicesAgency.Thesubjectorthe subject’slegalrepresentativeshouldbepromptlyinformedifnewinformationbecomesavailablethat mayberelevanttothesubject’swillingnesstocontinueparticipationinthetrial.Thecommunication ofthisinformationmustbedocumented. 10.4Neithertheinvestigatornoranyothermemberofstudyteamshouldcoerceorundulyinfluencea subjecttoparticipateorremaininatrial. 10.5Noneoftheoralinformationordocumentsconcerningthetrial,includingthewritteninformed consentform,shouldcontainanylanguageorclausesthatmaycausesubjectorthesubject'slegal representativetowaiveanylegalrights,orthatreleasestheprincipalinvestigatororothersinvolved theclinicaltrial,ortheinstitution,thesponsorortheiragentsfromliabilityfornegligence. 10.6Thesubjectorthesubject’slegalrepresentativemustbeinformedofallpertinentaspectsofthe clinicaltrial. 10.7Thelanguageusedintheoralandwritteninformationanddocumentsaboutthetrial,including thewritteninformedconsentform,shouldbenon-technical,asfaraspossible,andshouldbe understandabletothesubjectorthesubject'slegalrepresentativeandtheimpartialwitness,where applicable. 10.8Whenobtaininginformedconsent,thesubjectorthesubject'slegalrepresentativeshouldbe allowedampletimeandopportunitytoinquireaboutdetailsofthetrialandtodecidewhetherornotto participateinthetrial.Allquestionsaboutthetrialshouldbeansweredtothesatisfactionofthe subjectorthesubject'slegalrepresentative. 10.9Priortoasubject’sparticipationinthetrial,thewritteninformedconsentformshouldbehand- signedandpersonallydatedbythesubjectorbythesubject'slegalrepresentative,andbythephysician ordentistmemberoftheclinicaltrialteam,whoconductedtheinformedconsentdiscussion, indicatingthenameandsurnameofeachsignatory.Thewritteninformedconsentformmustbe initialedundereverypagebythesubjectorthesubject’slegalrepresentative,theimpartialwitness, andthememberofthetrialteamconcerned.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 25of34 10.10Ifthesubjectorthesubject’slegalrepresentativeisilliterateorvisuallyimpaired,animpartial witness,whomustnotbeamemberofthetrialteam,shouldbepresentduringtheentireinformed consentdiscussion.Afterthewritteninformedconsentformandanyotherwritteninformationtobe providedtosubjects,isreadandexplainedtothesubjectorthesubject’slegalrepresentative,andafter thesubjectorthesubject’slegalrepresentativehasorallyconsentedtothesubject’sparticipationinthe trialand,ifcapableofdoingso,hassignedanddatedtheinformedconsentform,thewitnessshould signanddatetheconsentform.Bysigningtheconsentform,thewitnessatteststhattheinformationin theconsentformandanyotherwritteninformationwasaccuratelyexplainedtoandunderstoodbythe subjectorthesubject'slegalrepresentative,andthatinformedconsentwasfreelygivenbythesubject orthesubject’slegalrepresentative. 10.11Theinformedconsentdiscussion,thewritteninformedconsentformandanyotherwritten informationtobeprovidedtosubjectsshouldatminimumincludeexplanationsofthefollowing: 10.11.1Thatthetrialinvolvesresearch. 10.11.2Thepurposeofthetrial. 10.11.3Thetrialtreatmentsandtheprobabilityforrandomassignmenttoeachtreatment. 10.11.4Thetrialprocedurestobefollowedorperformedonthesubject,includingallinvasive procedures. 10.11.5Thesubject'sresponsibilities. 10.11.6Thoseaspectsofthetrialthatareexperimental. 10.11.7Theforeseeablerisksorinconveniencestothesubject(and,whenapplicable,toanembryo, fetus,ornursinginfant). 10.11.8Thereasonablyexpectedbenefitsandwhenthereisnointendedclinicalbenefittothesubject, thatthesubjectwouldbemadeawareofthis. 10.11.9Thealternativeproceduresorcoursesoftreatmentthatmaybeadministeredtothesubject,and theirimportantpotentialbenefitsandrisks. 10.11.10Thecompensationortreatmentavailabletothesubjectintheeventoftrial-relatedinjury. 10.11.11Thepayment,ifany,tothesubjectforcoveringincidentalexpensessuchastravelandmeals. 10.11.12Thatthesubject'sparticipationinthetrialisvoluntaryandthatthesubjectmayrefuseto participateorwithdrawfromthetrial,atanytime,withoutpenaltyorlossofbenefitstowhichthe subjectisotherwiseentitled. 10.11.13Thatthemonitors,theauditors,theethicscommitteeandTurkishMedicinesandMedical DevicesAgencyorothercompetenthealthauthoritiesmayhavedirectaccesstothesubject'soriginal medicalrecords,butthatconfidentialityofallsuchinformationwouldbemaintained,andthat,by signingthewritteninformedconsentform,thesubjectorthesubject'slegalrepresentativeis authorizingsuchaccess. 10.11.14Thatrecordsidentifyingthesubjectwouldbekeptconfidentialandnotpubliclydisclosed pursuanttoapplicableregulatoryrequirements,andiftheresultsofthetrialarepublished,the subject’sidentitywouldremainconfidential. 10.11.15Thatthesubjectorthesubject'slegalrepresentativewouldbeinformedinatimelymannerif informationbecomesavailablethatmayberelevanttothesubject'swillingnesstocontinue participationinthetrial.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 26of34 10.11.16Thetelephonenumbersofpersonstocontactatanytimetoobtainfurtherinformation regardingthetrial,abouttheirrightsasaclinicaltrialsubject,andanyadverseeventsassociatedwith theclinicaltrial. 10.11.17Thecircumstancesorreasonsunderwhichthesubject'sparticipationinthetrialmaybe terminated. 10.11.18Theexpecteddurationofthesubject'sparticipationinthetrial. 10.11.19Theestimatednumberofsubjectswhowouldbeinvolvedinthetrial. 10.12Priortoparticipationinthetrial,thesubjectorthesubject'slegalrepresentativeshouldreceivea copyofthesignedanddatedwritteninformedconsentformandanyotherwritteninformation providedtothesubjects.Duringasubject’sparticipationinthetrial,thesubjectorthesubject’slegal representativeshouldreceiveacopyofthesignedanddatedconsentformupdatesandacopyofany amendmentstothewritteninformationprovidedtosubjects.Theprincipalinvestigatorandthesubject shouldkeepacopyoftheinformedconsentforms. 10.13Whenaclinicaltrialisonewheresubjectscanonlybeenrolledinthetrialwiththeconsentof thesubject’slegalrepresentative,thesubjectshouldbeinformedaboutthetrialtotheextent compatiblewiththesubject’sunderstandingand,ifcapable,thesubjectshouldaccept,signand personallydatethewritteninformedconsent. 10.14Exceptasdescribedin10.15,anon-therapeutictrial(i.e.atrialinwhichthereisnoanticipated directclinicalbenefittothesubject),shouldbeconductedinsubjectswhopersonallygiveconsentand whosignanddatethewritteninformedconsentform. 10.15Non-therapeutictrialsmaybeconductedinsubjectswithconsentofthelegalrepresentative providedthefollowingconditionsarefulfilled: 10.15.1Theobjectivesofthetrialcannotbemetbymeansofatrialinsubjectswhocangiveinformed consentpersonally. 10.15.2Theforeseeableriskstothesubjectsarelow. 10.15.3Thenegativeimpactonthesubject’swell-beingisminimizedandlow. 10.15.4Thetrialisnotprohibitedbylaw. 10.15.5Theapprovaloftheethicscommitteeisobtainedontheinclusionofsuchsubjects,andthe writtenfavorableopinioncoversthisaspect. Suchtrials,unlessanexceptionisjustified,shouldbeconductedinpatientshavingadiseaseor conditionforwhichtheinvestigationalproductisintended.Subjectsinthesetrialsshouldbe particularlycloselymonitoredandshouldbewithdrawniftheyappeartobedistressedinanyway. 10.16Inemergencysituations,whenpriorconsentofthesubjectisnotpossible,thewrittenconsentof thesubject'slegalrepresentative,ifpresent,shouldberequested,inorderthattherights,wellbeingand safetyofthesubjectscanbepreserved.Whenthesubject’slegalrepresentativeisnotavailable, enrolmentofthesubjectshouldrequiremeasuresdescribedintheprotocol,withdocumentedapproval bytheethicscommitteeandauthorizationbyTurkishMedicinesandMedicalDevicesAgency.The subjectorthesubject'slegalrepresentativeshouldbesubsequentlyinformedaboutthetrialassoonas possibleandconsenttocontinuethetrial,orbevoluntarilyremovedfromthentrial,asappropriate, shouldbeobtained. 10.17Whereaclinicaltrialinvolveschildrenwhoarecapableofconsenting,thewrittenconsentofthe child’sparentsorlegalguardian,whereapplicable,shouldbeobtainedinadditiontothechild’s consent.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 27of34 10.18Inclinicaltrialsinvolvingpatientswhoareinintensivecareorunconscious,writtenconsent shouldbereceivedafterdulyinformingthepatient’slegalrepresentativeornextofkin.Ifnoneare reachable,thepatientmaybeenrolledintheclinicaltrialundertheresponsibilityoftheprincipal investigatororanotherinvestigatorwhoisaphysicianordentist. 10.19ApprovalfromtheethicscommitteeandauthorizationfromTurkishMedicinesandMedical DevicesAgencymustbereceivedfortheinformationanddocuments,otherthantheinformedconsent form,whicharetobeprovidedtotrialsubjects. 10.20Thepatientcardsandpatientdiariesusedinapprovedandongoingclinicaltrialsmayberevised withpriornoticetoTurkishMedicinesandMedicalDevicesAgencyandtheethicscommittee,who mayrequiremodificationofsuchrevisionsifjustified. 11.INVESTIGATOR’SBROCHURE 11.1Theinvestigator’sbrochureisacompilationoftheclinicalandnonclinicaldataonthe investigationalproducts.Thisguidelineprovidesguidanceontheminimuminformationthatmustbe includedininvestigator’sbrochureandgivesadviceonitsdesign. 11.2Thepurposeoftheinvestigator’sbrochureistoprovidetheprincipalinvestigatorandothers involvedinthetrialwiththeinformationtofacilitatetheirunderstandingoftherationalefor,andtheir compliancewith,manykeyfeaturesoftheprotocol,suchasthedose,dosefrequencyorinterval, methodsofadministration,andsafetymonitoringprocedures. 11.3Theinvestigator’sbrochurealsoprovidesinsighttosupporttheclinicalmanagementofthestudy subjectsduringthecourseoftheclinicaltrial.Theinformationmustbepresentedinaconcise,simple, objective,balanced,andnon-promotionalformthatenablesapotentialinvestigatortounderstandit andmaketheirownunbiasedrisk-benefitassessmentoftheappropriatenessoftheproposedtrial. 11.4Amedicallyqualifiedpersonmaygenerallyparticipateintheeditingofaninvestigator’s brochure,butthismustbeapprovedbythedisciplinesthatgeneratedthedescribeddata. 11.5Itisexpectedthatthetypeandextentofinformationavailablewillvarywiththestageof developmentoftheinvestigationalproduct. 11.6IftheinvestigationalproductisauthorizedinTürkiye,anextensiveinvestigator’sbrochuremay notbenecessary.WherepermittedbyTurkishDrugandMedicalDevicesAgency,itmaybean appropriatealternativetothepackageleaflet,orlabeling,providedthatitincludescurrent, comprehensive,anddetailedinformationonallaspectsoftheinvestigationalproductthatmightbeof importancetotheprincipalinvestigator.IfaproductauthorizedinTürkiyeisbeingstudiedforanew use,aninvestigator’sbrochurespecifictothatnewusemustbeprepared. 11.7Theinvestigator’sbrochuremustbereviewedatleastannuallyandrevisedasnecessaryin compliancewithasponsor'swrittenprocedures.Frequentsrevisionmaybeappropriatedependingon thestageofdevelopmentandthegenerationofrelevantnewinformation.Howeverthisnew informationmustbepresentedtotheethicscommitteesforapproval.Ifitrequiresanamendmentin theinformedconsentformorthetrialprotocol,authorizationmustbeobtainedfromTurkish MedicinesandMedicalDevicesAgencyinadditiontoethicscommitteeapproval. 11.8Thesponsorisresponsibleforensuringthatanup-to-dateinvestigator’sbrochureismade availabletotheprincipalinvestigator.Inthecaseofaninvestigator-sponsoredtrial,theinvestigator mustdeterminewhetheraninvestigator’sbrochureisavailablefromthecommercialmanufacturer.If theinvestigator’sbrochureisprovidedbytheinvestigator,thentheymustprovidethenecessary informationtothestudyteam. 11.9Theinvestigator’sbrochuremustincludeatitlepageandaconfidentialitystatement: 11.9.1Titlepage:Thesponsor'sname,theidentityofeachinvestigationalproduct(i.e.,research number,chemicalorapprovedgenericnameandtradename,wherelegallypermissibleanddesiredby thesponsor).Itisalsosuggestedthataneditionnumber,andareferencetothenumberanddateofthe editionitsupersedes,beprovided.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 28of34 11.9.2ConfidentialityStatement:Thesponsormaywishtoemphasizethattheinvestigator’s brochureisaconfidentialdocument,solelyintendedtoinformandbeusedbytheinvestigator'steam, theethicscommitteeandTurkishMedicinesandMedicalDevicesAgency. 11.10Theinvestigator’sbrochuremustcontainthefollowingsections,eachwithliteraturereferences whereappropriate. 11.10.1 TableofContents:Atemplateforthetableofcontentsisgivenin11.12. 11.10.2 Summary:Ashortsummary(preferablynotexceedingtwopages)mustbegiven, highlightingthesignificantphysical,chemical,pharmaceutical,pharmacological,toxicological, pharmacokinetic,metabolicandclinicalinformationavailablethatisrelevanttothestageofclinical developmentoftheinvestigationalproduct. 11.10.3 Introduction:Abriefintroductorystatementmustbeprovidedthatcontainsthe chemicalname(andgenericandtradenameswhenapproved)oftheinvestigationalproducts,allactive substances,theinvestigationalproduct’spharmacologicalclassanditsexpectedpositionwithinthis class(e.g.advantages),therationaleforperformingresearchwiththeinvestigationalproducts,andthe anticipatedprophylactic,therapeuticordiagnosticindications.Finally,theintroductorystatementmust providethegeneralapproachtobefollowedinevaluatingtheinvestigationalproduct. 11.10.4 Physical,Chemical,andPharmaceuticalPropertiesandFormulation:Adescription mustbeprovidedofthesubstancescontainedintheinvestigationalproduct(includingthechemicalor structuralformulas),andabriefsummarymustbegivenoftherelevantphysical,chemical,and pharmaceuticalproperties.Topermitappropriatesafetymeasurestobetakeninthecourseofthetrial, adescriptionoftheformulationstobeused,includingexcipients,mustbeprovidedandjustifiedif clinicallyrelevant.Instructionsforthestorageandhandlingofthedosageformsmustalsobegiven. Anystructuralsimilaritiestootherknowncompoundsmustbementioned. 11.10.5 Non-clinicalStudies:Theresultsofallrelevantnonclinicalpharmacology,toxicology, pharmacokineticandmetabolismstudieswiththeinvestigationalproductmustbeprovidedin summaryform.Thissummarymustaddressthemethodologyused,theresults,andadiscussionofthe relevanceofthefindingstotheinvestigatedtherapeuticandanyunfavorableandunintendedeffectsin humans.Theinformationprovidedmayincludethefollowing,asappropriate,ifknown: 11.10.5.1 Animalspeciestested, 11.10.5.2 Numberandsexofanimalsineachgroup, 11.10.5.3 Unitdose(e.g.mg/kg,ml/kg) 11.10.5.4 Doseinterval, 11.10.5.5 Routeofadministration, 11.10.5.6 Durationofdosing 11.10.5.7 Informationonsystemicdistribution, 11.10.5.8 Durationofpost-exposurefollow-up, 11.10.5.9 Results,includingthefollowingaspects: 11.10.5.9.1Natureandfrequencyofpharmacologicalortoxiceffects, 11.10.5.9.2Severityorintensityofpharmacologicalortoxiceffects, 11.10.5.9.3Timetoonsetofeffects, 11.10.5.9.4Reversibilityofeffects, 11.10.5.9.5Durationofeffects, 11.10.5.9.6Doseresponse. Tabularformat/listingsmustbeusedwheneverpossibletoensuretheclarityofthepresentation.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 29of34 Thefollowingsectionsmustdiscussthemostimportantfindingsfromthestudies,includingthedose responseofobservedeffects,therelevancetohumans,andanyaspectstobestudiedinhumans. Whereappropriate,theeffectiveandnontoxicdosefindingsinthesameanimalspeciesmustbe compared(i.e.,thetherapeuticindexmustbediscussed).Therelevanceofthisinformationtothe proposedhumandosingmustbeaddressed.Wheneverpossible,comparisonsmustbemadeintermsof blood/tissuelevelsratherthanonamg/kgbasis. a) NonclinicalPharmacology:Asummaryofthepharmacologicalaspectsoftheinvestigational productand,whereappropriate,itssignificantmetabolitesstudiedinanimals,mustbeincludedinthe investigator’sbrochure.Thesummarymustincorporatestudiesthatassesspotentialtherapeutic activity(e.g.efficacymodels,receptorbindingandspecificity)aswellasthosethatassesssafety(e.g. specialstudiestoassesspharmacologicalactionsotherthantheintendedtherapeuticeffects). b) PharmacokineticsandProductMetabolisminAnimals:Asummaryofthepharmacokinetics andbiologicaltransformationanddispositionoftheinvestigationalproductinallspeciesstudiedmust begiven.Thediscussionofthefindingsmustaddresstheabsorptionandthelocalandsystemic bioavailabilityoftheinvestigationalproductanditsmetabolites,andtheirrelationshiptothe pharmacologicalandtoxicologicalfindingsinanimalspecies. c) Toxicology:Asummaryofthetoxicologicaleffectsfoundinrelevantstudiesconductedin differentanimalspeciesmustbedescribedunderheadingssingledose,repeateddose,carcinogenicity, specialstudies(e.g.irritancyandsensitization),reproductivetoxicity,andgenotoxicity,mutagenicity. 11.10.6 EffectsinHumans:Athoroughdiscussionoftheknowneffectsoftheinvestigational productsinhumansmustbeprovided,includinginformationonpharmacokinetics,metabolism, pharmacodynamics,doseresponse,safety,efficacy,andotherpharmacologicalactivities.Where possible,asummaryofeachcompletedclinicaltrialmustbeprovided.Informationmustalsobe providedregardingresultsofanyuseoftheinvestigationalproductsotherthanfrominclinicaltrials (suchasfromexperienceduringmarketing). 11.10.7 PharmacokineticsandProductMetabolisminHumans:Asummaryofinformationon thepharmacokineticsoftheinvestigationalproductsmustbepresented,includingthefollowing,if available: 11.10.7.1 Pharmacokinetics(includingmetabolism,asappropriate,andabsorption,plasma proteinbinding,andelimination) 11.10.7.2 Bioavailabilityoftheinvestigationalproduct(absolute,wherepossible,orrelative) usingareferencedosageform, 11.10.7.3 Populationsubgroups(e.g.gender,age,andimpairedorganfunction), 11.10.7.4 Interactions(e.g.product-productinteractionsandinteractionwithfood), 11.10.7.5 Otherpharmacokineticdata 11.10.8 SafetyandEfficacy:Asummaryofinformationmustbeprovidedaboutthe investigationalproducts'(includingthoseofitsmetabolites,whereappropriate)safety, pharmacodynamics,efficacyanddoseresponsethatwereobtainedfromprevioustrialsinsubjects.In caseswheremanyclinicaltrialshavebeencompleted,theuseofsummariesofsafetyandefficacy acrossmultipletrialsinsubgroupsbyindicationmayprovideaclearpresentationofthedata.Tabular summariesofadversedrugreactionsforalltheclinicaltrials(includingthoseforallthestudied indications)mustbeprovided.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 30of34 Differencesinadversedrugreactionpatterns/incidencesacrossindicationsorsubgroupsmustbe discussed.Theinvestigator’sbrochuremustprovideadescriptionofthepossiblerisksandadverse drugreactionstobeanticipatedonthebasisofpriorexperienceswiththeproductunderinvestigation andwithotherproducts.Adescriptionmustalsobeprovidedoftheprecautionsorspecialmonitoring tobedoneaspartoftheinvestigationaluseoftheproducts. 11.10.9 MarketingExperience:Theinvestigator’sbrochuremustidentifycountrieswherethe investigationalproducthasbeenmarketedorapproved.Anysignificantinformationarisingfromthe marketedusemustbesummarized(e.g.formulations,dosages,routesofadministration,andadverse productreactions).Theinvestigator’sbrochuremustalsoidentifyallthecountrieswherethe investigationalproductdidnotreceiveapproval/authorizationformarketingorwaswithdrawnfrom market/authorization. 11.10.10 SummaryofDataandGuidancefortheInvestigator:Thissectionmustprovidean overalldiscussionofthenonclinicalandclinicaldata,andmustsummarizetheinformationfrom varioussourcesondifferentaspectsoftheinvestigationalproducts,whereverpossible.Inthisway,the principalinvestigatorcanbeprovidedwiththemostinformativeinterpretationoftheavailabledata andwithanassessmentoftheimplicationsoftheinformationforfutureclinicaltrials.Where appropriate,thepublishedreportsonrelatedproductsmustbediscussed.Thiscouldhelptheprincipal investigatororotherinvestigatorstoanticipateadversedrugreactionsorotherproblemsinclinical trials.Theoverallaimofthissectionistoprovidetheinvestigatorwithaclearunderstandingofthe possiblerisksandadversereactions,andofthespecifictests,observationsandprecautionsthatmaybe neededforaclinicaltrial.Thisunderstandingmustbebasedontheavailablephysical,chemical, pharmaceutical,pharmacological,toxicologicalandclinicalinformationontheinvestigational products.Guidancemustalsobeprovidedtotheclinicalinvestigatorontherecognitionandtreatment ofpossibleoverdoseandadversedrugreactionsthatarebasedonprevioushumanexperienceandon thepharmacologyoftheinvestigationalproduct. 11.11Templatefortitlepagefortheinvestigator’sbrochure: Nameofthesponsor Product Clinicaltrialnumber Names:chemicalname,genericname(ifapproved) Inventednames(iflegallypermittedandrequestedbythesponsor) Editionnumberoftheinvestigator’sbrochure Issuingdateoftheinvestigator’sbrochure Thenumberanddateoftheversionsupersededbytheinvestigator’sbrochure 11.12Templatefortableofcontentsfortheinvestigator’sbrochure: Confidentialitystatement(optional) SignaturePage(optional) Tableofcontents Summary Introduction Physical,chemical,andpharmaceuticalpropertiesandformulation NonclinicalStudies Nonclinicalpharmacology Pharmacokineticsandproductmetabolisminanimals Toxicology EffectsinHumans Pharmacokineticsandproductmetabolisminhumans Safetyandefficacy

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 31of34 Marketingexperience Summaryofdataandguidancefortheinvestigator Referencestopublicationsandreports:Thesereferencesshouldbeincludedattheendofeach section. Annexes(ifavailable) 12.ESSENTIALDOCUMENTSFORCONDUCTINGACLINICALTRIAL 12.1EssentialDocumentsarethosedocumentswhichindividuallyandcollectivelypermitevaluation oftheconductofatrialandthequalityofthedataproduced.Thesedocumentsservetodemonstrate thecomplianceoftheprincipalinvestigatororotherinvestigators,sponsorandmonitorwiththe standardsofgoodclinicalpracticeandwithallapplicableregulatoryrequirements. 12.2Providingthesedocumentsinatimelymannercangreatlyassistinthesuccessfulmanagementof atrialbytheprincipalinvestigator,otherinvestigators,sponsorandmonitor. 12.3Thesedocumentsshouldbealsoauditedbythesponsor'sindependentauditfunctionand inspectedbyTurkishMedicinesandMedicalDevicesAgencyaspartoftheprocesstoconfirmthe validityofthetrialconductedandtheintegrityofdatacollected. 12.4Thedocumentsaregroupedinthreesectionsaccordingtothestageofthetrialduringwhichthey wouldnormallybegeneratedbeforetheclinicalphaseofthetrialcommences,duringtheclinical performanceofthetrial,andaftercompletionorterminationofthetrial. 12.5Adescriptionisgivenofthepurposeofeachdocument.Itisspecifiedwhetheritmustbefiledin eithertheprincipalinvestigatororsponsorfiles,orboth.Itisacceptabletocombinesomeofthe documents,providedtheindividualelementsarereadilyidentifiable. 12.6Trialmasterfilesmustbeestablishedatthebeginningofthetrial,bothattheprincipal investigator’sandatthesponsor’ssite.Afinalclose-outofatrialmayonlybedonewhenthemonitor hasreviewedboththeprincipalinvestigatorandthesponsorfilesandconfirmedthatallnecessary documentsareintheappropriatefiles. 12.7Anyorallofthedocumentsaddressedinthisguidelinearesubjecttoauditbythesponsor’s auditorandinspectionbyTurkishMedicinesandMedicalDevicesAgencyorothercompetenthealth authorities. 12.8Thesponsorandtheprincipalinvestigatorshouldmaintainarecordofthelocationsoftheir respectiveessentialdocuments.Thearchivingsystemshouldfacilitatedocumentidentification,search andretrieval. 12.9Dependingontheactivitiesbeingcarriedout,individualtrialsmayrequireadditionaldocuments notspecificallymentionedintheessentialdocumentlist.Thesponsorortheprincipalinvestigator shouldincludetheseaspartofthetrialmasterfile. 12.10Thesponsorshouldensurethattheinvestigatorhascontrolofandcontinuousaccesstothecase reportformdatareportedtothesponsor.Thesponsorshouldnothaveexclusivecontroloverthose data.Whenacopyisusedtoreplaceanoriginaldocument,thecopyshouldfulfilltherequirementsfor certifiedcopies. 12.11Beforetheclinicalphaseofthetrialformallystarts,thefollowingdocumentsatminimummust bereadyandinfile: 12.11.1Theinvestigator’sbrochuretodocumentthatrelevantandcurrentinformationaboutthe investigationalproducthasbeenprovidedtotheinvestigator, 12.11.2Thestudyprotocolanditsamendments,ifany,andtheCRF(maybeindraftform,but approvaloftheethicscommitteeshouldbereceivedbythetimefirstsubjectisenrolled),signedto documenttheinvestigatorandsponsor’sagreementtothestudyprotocol,amendmentsandtheCRF,

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 32of34 12.11.3TheICF,otherwritteninformationandtheadvertisementusedforenrollingpatients,ifany,to documentthatsubjectshavereceivedtheinformedconsentformandwritteninformationtosupport theirfullyinformedconsent,andthatenrollmentofpatientswasappropriateandfreefromany coerciveelements, 12.11.4Financialaspectsofthestudy, 12.11.5Insurancecoverage,whererequired, 12.11.6Signedagreementsbetweenthepartiesconcerned, 12.11.7Ethicscommitteeapproval, 12.11.8AuthorizationfromTurkishMedicinesandMedicalDevicesAgencyinlinewiththe applicableregulatoryrequirements, 12.11.9Curriculumvitaeofthecoordinator,administrativeliaison,principalinvestigatorsandother investigators, 12.11.10Normalvaluesorratesfortestsspecifiedinthestudyprotocolandlaboratorydocuments,if any, 12.11.11Asampleofthelabelusedontheinvestigationalproduct,inlinewiththeapplicable regulatoryrequirements, 12.11.12Instructionsforhandlingtheinvestigationalproducts,ifnotaddressedinthestudyprotocol orinvestigator’sbrochure,todocumentinstructionsneededtoensureproperstorage,packaging, dispensinganddispositionofinvestigationalproductsandthetrial-relatedmaterials, 12.11.13Shippingrecordsforinvestigationalproductsandtrial-relatedmaterialstodocument shipmentdates,batchnumbersandmethodofshipmentofinvestigationalproductsandtrial-related materials, 12.11.14Certificateofanalysisinvestigationalproductsshipped, 12.11.15Unblindingmethodsforblindedtrials, 12.11.16Therandomizationlist, 12.11.17Thepre-trialmonitoringreporttodocumentsuitabilityoftheinvestigationalsite, 12.12Inadditiontohavingonfiletheabovedocuments,thefollowingshouldbeaddedtothefiles duringtheclinicalphaseofthetrialasevidencethatallnewrelevantinformationisdocumentedasit becomesavailable: 12.12.1.Investigator’sbrochureupdates, 12.12.2.Anyrevisionstothedocuments,includingthestudyprotocol,ICForCRF, 12.12.3AuthorizationfromTurkishMedicinesandMedicalDevicesAgency,inadditiontoethics committeeapproval,fortheamendments,ifnecessary, 12.12.4Replacementofcoordinator,administrativeliaison,principalinvestigatororother investigators, 12.12.5Changestonormalvaluesorratesforthetestsspecifiedinthetrialprotocol,andlaboratory documents,ifany, 12.12.6Monitorreports, 12.12.7Notesfromimportantcommunications,otherthaninvestigationalsitevisits(e.g.notesof phonecall,meetingnotes), 12.12.8ICF,signedandgiveninlinewiththeapplicableregulatoryrequirements,andsource documents, 12.12.9CRF,signed,datedandcompleted, 12.12.10CRFcorrections, 12.12.11Safetynotifications, 12.12.12Subjectscreeninglogs, 12.12.13Subjectidentifierlist,

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 33of34 12.12.14Recordstodocumentthattheinvestigationalproductshavebeenusedaccordingtothe protocol, 12.12.15Signaturepagetodocumentsignaturesandinitialsofindividualsauthorizedtoenteror modifyCRFs. 12.13Aftercompletionorterminationofthetrial,allofthedocumentsidentifiedinsections12.11and 12.12shouldbeinthefiletogetherwith: 12.13.1Recordsandaccountingofinvestigationalproductuseattheinvestigationalsite, 12.13.2Documentationofinvestigationalproductdestructioninlinewiththeapplicableregulatory requirements, 12.13.3Completedsubjectidentifierslist, 12.13.4Finaltrialclose-outmonitoringreport, 12.13.5Documentationofanyauditsandinspections,ifavailable, 12.13.6Documentationofanyinstancesofunblinding,ifapplicable, 12.13.7ThefinalreporttotheethicscommitteeandTurkishMedicinesandMedicalDevicesAgency, 12.13.8Clinicaltrialreport. 13.MISCELLANEOUSPROVISIONS 13.1ItissufficienttonotifytheethicscommitteeandTurkishMedicinesandMedicalDevices Agencywhenextendinginsurancetermwithoutchanginganyoftheinsuranceconditionsasspecified ontheinsurancecertificatesapprovedbytheethicscommitteeandauthorizedbyTurkishMedicines andMedicalDevicesAgency. 13.2Theprincipalinvestigatormay,whereappropriate,appointclinicaltrialnurses,fieldassociates, monitors,clinicaltrialpharmacistsorothercompetentpersonneltoassistwiththeconductofthe clinicaltrial,providedthatTurkishMedicinesandMedicalDevicesAgencyandtheethicscommittee concernedaredulynotifiedofsuchappointments.However,theethicscommitteeorTurkish MedicinesandMedicalDevicesAgencymayannulsuchappointmentswithjustification. 13.3Aprincipalinvestigatorwhohasbeenappointedinthatcapacitytoleadaclinicaltrialapproved bytheethicscommitteeandauthorizedbyTurkishMedicinesandMedicalDevicesAgencymaybe replacedbynotifyingTurkishMedicinesandMedicalDevicesAgencyandtheethicscommittee. However,theethicscommitteeorTurkishMedicinesandMedicalDevicesAgencymayannulsuch appointmentswithjustification. 13.4Formulti-centerinternationalstudies,itissufficienttoinformtheethicscommitteefornon- safetyrelatedchangesintheinvestigator’sbrochure,protocolamendmentsorICFrevisions,which willnotbeimplementedinTürkiye. 13.5ACRFmustbepresentedforapprovalandauthorizationatthetimeofinitialapplicationtothe ethicscommitteeandTurkishMedicinesandMedicalDevicesAgency,respectively,toconducta clinicaltrial. 13.6ItissufficienttonotifytheethicscommitteeforchangesinelectronicCRFsofatechnicalnature whichdonotaffectvalidation(e.g.changesthatstreamlinerespondingtodatainanethicscommittee- andTurkishMedicinesandMedicalDevicesAgency-approvedversionoftheCRF,orenabling automatedinquirycreationaterroneousdataentry,orversionchangessuchasinterfaceimprovements withoutaqualitativeorquantitativeimpactonthedata). 13.7Asingleethicscommitteedecisionissufficientformulti-centerclinicaltrials,whichmustbe issuedbytheethicscommitteeoftheinstitutionhostingthecoordinatingsiteor,wherenoneis available,fromanethicscommitteeofaninvestigationalsitegeographicallyclosesttothe coordinatingsite.Forsingle-centerclinicaltrials,theapprovalshouldbereceivedfromtheethics committeeattheinstitutionhostingtheclinicaltrialor,wherenoneisavailable,fromanethics committeegeographicallyclosesttotheinvestigationalsite.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-01 29.12.1995 01.02.2024 08 34of34 14.EFFECTIVENESS ThisGuidelinebecomeseffectiveonthedateitisapproved. 15.ENFORCEMENT REVISIONHISTORY RevisionNumber RevisionDate RationaleandDescription 00 29.12.1995 Updatebeforeimplementationofthequality managementsystem. 01 28.01.2009 Updatebeforeimplementationofthequality managementsystem. 02 28.05.2010 Updatebeforeimplementationofthequality managementsystem. 03 10.12.2010 Updatebeforeimplementationofthequality managementsystem. 04 06.12.2011 Updatebeforeimplementationofthequality managementsystem. 05 23.08.2011 Updatebeforeimplementationofthequality managementsystem. 06 17.04.2013 Updatebeforeimplementationofthequality managementsystem. 07 15.07.2014 Updatebeforeimplementationofthequality managementsystem. 08 01.02.2024 Updatebeforeimplementationofthequality managementsystem.